 |
Meet-the-Expert | Simultaneous
sessions | Hematology-in-Focus | Lunch
debates | EHA Education forum | EHA
Business meeting | Plenary session I | Presidential
symposium | Poster session II | Meetings
by European Networks
Please do not forget to pre-register for
the Meet-The-Expert
sessions in the registration area ! |
MEET-THE-EXPERT 1
07.30 - 08.15, Salon 3 (Villa Sarasin, ground floor)
W. Hiddeman
(University Hospital Munich, München, Germany)
MEET-THE-EXPERT 2
07.30 - 08.15, Salon 11 (Villa Sarasin, 1st floor)
F.J. Batlle (Complexo Hospitalario Universitario
Juan Canalejo, A Coruna, Spain)
MEET-THE-EXPERT
3
07.30 - 08.15, Salon 17 (Villa Sarasin, 1st floor)
A.
Orfao (University of Salamanca, Salamanca, Spain)
MEET-THE-EXPERT 4
07.30 - 08.15, Salon 1 (Villa Sarasin, ground floor)
P. Sonneveld (Erasmus Medical
Center, Rotterdam, The Netherlands)
MEET-THE-EXPERT
5
07.30 - 08.15, Salon 2 (Villa Sarasin, ground floor)
G.
Barosi (IRCCS Policlinico S. Matteo, Pavia, Italy)
MEET-THE-EXPERT 6
07.30 - 08.15, Salon 5 (Villa Sarasin, ground floor)
V.
Hoffbrand (Royal Free Hospital, London, United Kingdom)
MEET-THE-EXPERT 7
07.30 - 08.15, Salon 13 (Villa Sarasin, 1st floor)
F. Demarmels Biasiutti (University Hospital Bern, Bern, Switzerland)
|
|
MEET-THE-EXPERT
8
11.30 - 12.15, Salon 3 (Villa Sarasin, ground floor)
STEM CELLS
A. Ho (University Hospital Heidelberg, Heidelberg, Germany)
MEET-THE-EXPERT 9
11.30 - 12.15, Salon 5 (Villa Sarasin, ground floor)
T. Barbui (Ospedali Riuniti di Bergamo, Bergamo, Italy)
MEET-THE-EXPERT 10
11.30 - 12.15, Salon 11 (Villa Sarasin, 1st floor)
B. Falini (University of Perugia, Perugia, Italy)
MEET-THE-EXPERT
11
11.30 - 12.15, Salon 1 (Villa Sarasin, ground floor)
H. Büller (Medical Center Amsterdam, Amsterdam, The Netherlands)
MEET-THE-EXPERT 12
11.30 - 12.15, Salon 13 (Villa Sarasin, 1st floor)
B. Mansouri Taleghani (Medical University Bern, Bern, Switzerland)
MEET-THE-EXPERT 13
11.30 - 12.15, Salon 17 (Villa Sarasin, 1st floor)
S. Amadori (University Tor Vergata, Rome, Italy)
MEET-THE-EXPERT
14
11.30 - 12.15, Salon 2 (Villa Sarasin, ground floor)
R. Galanello (Istituto Ospedale Microcitemico, Cagliari, Italy) |
SIMULTANEOUS SESSION
08:30 - 09:45, Room A (Geneva Palexpo)
| Chairs: |
A. Urbano-Ispizua (University of Barcelona, Barcelona,
Spain)
A. Carella (Azienda Ospedaliera San Martino, Genoa, Italy) |
| 08:30 - 08:45 |
IN VITRO SEPARATION
OF GVL EFFECT AND GVHR FROM ANTILEUKEMIA CTL LINES: A PERSPECTIVE
FOR ADOPTIVE IMMUNOTHERAPY AFTER ALLOGENEIC HSCT
D. Montagna, F. Locatelli, L. Daudt, I. Turin, E. Montini, D.
Lisini, M. Zecca, A. Moretta, R. Maccario (Univ. of Pavia, IRCCS
Pol. San Matteo, Pavia, Italy) |
| 08:45 - 09:00 |
ALLOGENEIC PERIPHERAL BLOOD
STEM CELL TRANSPLANT VS. BONE MARROW TRANSPLANT IN THE MANAGEMENT
OF HEMATOLOGICAL MALIGNANCIES: AN INDIVIDUAL PATIENT DATA META-ANALYSIS
OF 9 RANDOMIZED TRIALS
Stem Cell Trialists’ group (Tampa, USA) |
| 09:00 - 09:15 |
LONG TERM OUTCOME AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION FOR CML
J.M. Goldman, J.D. Rizzo, K.A. Sobocinski, M.J. Zhang, J.P.
Klein, S. Ketelson, S. Giralt, M.M. Horowitz (Imperial College/Hammersmith
Hospital, London, United Kingdom) |
| 09:15 - 09:30 |
SIROLIMUS AND TACROLIMUS
AS GRAFT-VS.-HOST DISEASE PROPHYLAXIS IN ALLOGENEIC STEM CELL
TRANSPLANTATION: THE DANA-FARBER CANCER INSTITUTE EXPERIENCE
C. Cutler, L. Li, H.T. Kim, E. Alyea, V.T. Ho, S.J. Lee, D.C.
Fisher, R. Schlossman, E. Hochberg, D. Miklos, S. Sonis, R.J.
Soiffer, J.H. Antin (Dana-Farber Cancer Institute, Boston, USA) |
| 09:30 - 09:45 |
G-CSF INCREASES THE NUMBER
OF PERIPHERAL BLOOD DENDRITIC CELLS CD16+ AND THE EXPRESSION
OF THE COESTIMULATORY MOLECULE CD86+. IMPLICATIONS IN ALLOGENEIC
TRANSPLANTATION.
A. Urbano Ispizua, R. Martino, M. Batlle, C. Herrera, J.A. Pérez-Simón,
P. Marín, J. Sierra, E. Montserrat, C. Talarn (Hospital
Clinic, Barcelona, Spain) |
|
|
SIMULTANEOUS SESSION
08:30 - 09:45, Room B (Geneva Palexpo)
| Chairs: |
T. de Witte (University Medical Center St. Radboud,
Nijmegen, The Netherlands)
P. Fenaux (Hôpital Avicenne, Bobigny, France) |
| 08:30 - 08:45 |
A NEW DISEASE
DEFINITION OF LOW GRADE MDS BASED ON THE EXPRESSION OF CYTOPENIA
AND DYSPLASIA IN ONE OR MORE LINEAGES AT DIAGNOSIS IMPROVES
ON THE FAB AND WHO CLASSIFICATION
E.R. Verburgh, R. Achten, C. Brusselmans, V. Louw, M. Delforge,
P. Vandenberghe, A. Hagemeijer, M. Boogaerts, C. De Wolf-Peeters,
G. Verhoef (UZ Gasthuisberg, Leuven, Belgium) |
| 08:45 - 09:00 |
270 NRAS, FLT3 AND TP53 MUTATIONS
IN PATIENTS WITH MDS AND A DEL(5Q)
C. Fidler, F. Watkins, D.T. Bowen, T.J. Littlewood, J.S. Wainscoat,
J. Boultwood (University of Oxford, Oxford, United Kingdom) |
| 09:00 - 09:15 |
FLOW CYTOMETRIC EVALUATION
OF MARROW DYSPLASIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
M.L. Malcovati, M. Lunghi, L. Vanelli, M.G. Della Porta, C.
Pascutto, E. Travaglino, P. Bernasconi, R. Invernizzi, M. Lazzarino,
M. Cazzola (University of Pavia Medical School, Pavia, Italy) |
| 09:15 - 09:30 |
DETECTION OF MYELOBLASTIN
(MBN) GENE OVEREXPRESSION IN PATIENTS AFFECTED BY MYELODYSPLASTIC
SYNDROMES AND ACUTE MYELOID LEUKAEMIAS
D. Cilloni, S. Carturan, E. Gottardi, F. Messa, I. Defilippi,
F. Arruga, M. Fava, A. Guerrasio, F. Lo Coco, G. Saglio (University
of Turin, Orbassano, Italy) |
| 09:30 - 09:45 |
MITOCHONDRIAL ABNORMALITIES
IN LOW-RISK MYELODYSPLASTIC SYNDROMES: ABERRANT MT FERRITIN
ACCUMULATION IS A VERY EARLY EVENT IN RARS ERYTHROPOIESIS
R. Tehranchi, R. Invernizzi, B. Zhivotovsky, B. Fadeel, A.M.
Forsblom, E. Travaglino, J. Samuelsson, R. Hast, L. Nilsson,
M. Cazzola, R. Wibom, E. Hellström-Lindberg (Karolinska
University Hospital, Huddinge, Stockholm, Sweden) |
|
SIMULTANEOUS SESSION
08:30 - 09:45, Room C (Geneva Palexpo)
| Chairs: |
G. Barosi (IRCCS Policlinico S. Matteo, Pavia,
Italy)
G. Dighiero (Institute Pasteur, Paris, France) |
| 08:30 - 08:42 |
A NOVEL 53BP1-PDGFRB
FUSION AS TARGET FOR IMATINIB IN A PATIENT WITH BCR-ABL NEGATIVE
CHRONIC MYELOID LEUKEMIA AND A T(5;15)(Q33;Q22)
N.C.P. Cross, F.H. Grand, S. Burgstaller, T. Kühr, A. Chase,
E.J. Baxter, G. Webersinke, J. Thaler, N.C.P. Cross (Salisbury
District Hospital, Salisbury, United Kingdom) |
| 08:42 - 08:54 |
PEGYLATED INTERFERON ALPHA
(PEGINTRON) FOR THE TREATMENT OF HIGH-RISK ESSENTIAL THROMBOCYTHEMIA:
RESULTS OF A PHASE II STUDY
C. Langer, E. Lengfelder, J. Thiele, H.M. Kvasnicka, H. Pahl,
A. Matzdorff, B. Stade, S. Schauer, M. Moessner, H. Gisslinger,
M. Griesshammer (University of Ulm, Ulm, Germany) |
| 08:54 - 09:06 |
HMGA2 DYSREGULATION IN MYELOFIBROSIS
WITH MYELOID METAPLASIA (MMM) VERSUS OTHER PH-NEGATIVE CHRONIC
MYELOPROLIFERATIVE DISORDERS AND MYELODYSPLASTIC SYNDROMES
J.L. Demory, J. Andrieux, B. Dupriez, C. Bilhou-Nabera, E. Lippert,
A. Charpentier, N. Grardel, V. Praloran, J.L. Lai, J.L. Demory
(Université Catholique de Lille, Lille, France) |
| 09:06 - 09:18 |
RISK FACTORS FOR PROGRESSION
TO ACUTE LEUKEMIA IN PATIENTS WITH POLYCYTHEMIA VERA ENROLLED
IN THE ECLAP STUDY
V. Caruso, G. Finazzi, R. Marchioli, G. Tognoni, T. Barbui (Consorzio
Mario Negri Sud, Santa Maria Imbaro. Chieti, Italy) |
| 09:18 - 09:30 |
ITALIAN COOPERATIVE STUDY
ON IDIOPATHIC HYPEREOSINOPHILIC SYNDROME (HES): FIP1-L1/PDGFRA
REARRANGEMENT CAN BE EFFECTIVELY TREATED WITH IMATINIB
G. Martinelli, D. Cilloni, E. Ottaviani, M. Malagola, F. Pane,
M. Rondoni, M. Tiribelli, C. Bosi, E. Zuffa, T. Grafone, E.
Gottardi, S. Merante, M. Cazzola, G. Saglio, M. Baccarani (Inst.
of Hematology and Medical
Oncology, Bologna, Italy) |
| 09:30 - 09:42 |
THE QUANTITATIVE ASSESSEMENT
OF WT1 ALLOWS TO IDENTIFY THE HYPEREOSINOPHILIC SYNDROME PATIENTS
AND TO PREDICT RESPONSE TO IMATINIB THERAPY
D. Cilloni, F. Messa, E. Giugliano, E. Gottardi, F. Arruga,
I. Defilippi, A. Serra, M. Fava, E. Messa, S. Carturan, T. Sacha,
M. Baccarani, G. Saglio (University of Turin, Orbassano, Italy) |
| 09:42 - 09:45 |
| DISCUSSION |
|
|
SIMULTANEOUS SESSION
08:30 - 09:45, Le Jura (Geneva Palexpo)
| Chairs: |
P. Giangrande (Churchill Hospital, Oxford, United
Kingdom)
M. Cattaneo (Ospedale San Paolo, University of Milano, Milan,
Italy) |
| 08:30 - 08:42 |
IS FACTOR V LEIDEN
A RISK FACTOR FOR THROMBOTIC MICROANGIOPATHIES WITHOUT SEVERE
ADAMTS-13 DEFICIENCY?
S. Krieg, J.D. Studt, B. Lämmle, J.A. Kremer Hovinga (Central
Hematology Laboratory, Bern, Switzerland) |
| 08:42 - 08:54 |
IN VITRO EXPRESSION STUDY
OF A NEW MUTATION (R1308L) FOUND IN A FAMILY WITH TYPE 2B VON
WILLEBRAND DISEASE CHARACTERIZED BY ALL SET OF MULTIMERS IN
PLASMA AND NO THROMBOCYTOPENIA AFTER DESMOPRESSIN
B.L. Baronciani, A.B. Federici, G. Cozzi, M. Beretta, C. Mistretta,
M.T. Canciani, P.M. Mannucci (IRCCS Maggiore Hospital, Milan,
Italy) |
| 08:54 - 09:06 |
UNLIKE HEPARINS, FONDAPARINUX
DOES NOT ADVERSELY AFFECT THE METABOLISM OF CULTURED HUMAN OSTEOBLASTS
G. Matziolis, C. Perka, A. Disch, H. Zippel (Charite University
Hospital,
Berlin, Germany) |
| 09:06 - 09:18 |
SPECIFIC ROLES OF TISSUE
FACTOR-EXPRESSING CELLS AND PLASMA-ASSOCIATED COAGULATION REACTIONS
IN REGULATING SPATIAL GROWTH OF FIBRIN CLOT
N.A. Ananyeva, M.V. Ovanesov, F.I. Ataullakhanov, E.L. Saenko
(J. Holland Laboratory, American Red Cross, Rockville, USA) |
| 09:18 - 09:30 |
APTT BIPHASIC WAVEFORM PERSISTENCE
IN SEPTIC PATIENTS IS ASSOCIATED WITH A HIGH MORTALITY RISK
I. Alonso, C. Bradstreet, P. Dechamps, F. Vandermijnsbrugge,
E. Vanremoortle, B. Cantinieaux, C. Bradstreet (CHU Saint-Pierre
Hospital, Brussels, Belgium) |
| 09:30 - 09:42 |
THERAPY WITH HIGH-DOSE DEXAMETHASONE
IN PREVIOUSLY UNTREATED PATIENTS AFFECTED BY IDIOPATHIC THROMBOCYTOPENIC
PURPURA (ITP). FROM THE GIMEMA ITP STUDY GROUP
M.G. Mazzucconi, S. Bernasconi, P. Fazi, F. Mandelli (Hematology,
Rome, Italy) |
| 09:42 - 09:45 |
| DISCUSSION |
|
SIMULTANEOUS SESSION
08:30 - 09:45, Room D (Geneva Palexpo)
| Chairs: |
J.J.M. van Dongen (Erasmus Medical Center, Rotterdam,
The Netherlands)
D. Colomer (Hospital Clinic, Barcelona, Spain) |
| 08:30 - 08:45 |
BIASED USAGE
OF VH3-72 AND IGVK GENES AND HOMOLOGOUS IGVH AND IGVL CDR3S
IN HIGHLY STABLE B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: IMPLICATIONS
FOR ANTIGEN RECOGNITION IN LEUKEMOGENESIS
D. Rossi, A. Guarini, D. Capello, E. Berra, F.R. Mauro, M. Cerri,
J. Logan, R. Foà, G. Gaidano (Amedeo Avogadro University,
Novara, Italy) |
| 08:45 - 09:00 |
LIPOPROTEIN LIPASE (LPL)
IS A PREDICTOR OF IGVH MUTATIONAL STATUS IN PATIENTS WITH CHRONIC
LYMPHOCYTIC LEUKEMIA
D. Heintel, D. Kienle, E. Kroemer, I. Schwarzinger, A. Gleiî,
M. Shehata, T. Le, C. Mannhalter, A. Chott, H. Döhner,
S. Stilgenbauer, C. Fonatsch, A. Gaiger, U. Jäger (Medical
University of Vienna, Vienna, Austria) |
| 09:00 - 09:15 |
GENE EXPRESSION PROFILES
IN FOLLICULAR LYMPHOMA IN RELATION TO PREDICTION OF RESPONSE
TO CHOP CHEMOTHERAPY
E. Björck, O. Landgren, M. Björkholm, A. Porwit-MacDonald,
M. Nordenskjöld (Karolinska University Hospital, Stockholm,
Sweden) |
| 09:15 - 09:30 |
FUNCTIONAL IMPAIRMENT OF
THE ATM-P53 PATHWAY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: SUPPRESSION
BY BASIC FIBROBLAST GROWTH FACTOR AS AN ALTERNATIVE TO P53/ATM
MUTATION
A.R. Pettitt, V.V. Romanov, K. Lin, P.D. Sherrington (Royal
Liverpool University Hospital, Liverpool, United Kingdom) |
| 09:30 - 09:45 |
| DISCUSSION |
|
|
SIMULTANEOUS SESSION
11:30 - 12:45, Room A (Geneva Palexpo)
| Chairs: |
J-P. Cartron (Inserm U76, Paris, France)
C. Hershko (Shaare Zedek Medical Center, Jerusalem, Israel) |
| 11:30 - 11:45 |
MUTATIONS IN
THE VON-HIPPEL-LINDAU (VHL) GENE AND VHL- HAPLOTYPE ANALYSIS
IN PATIENTS WITH APPARENTLY CONGENITAL ERYTHROCYTOSIS
H.C. Cario, K. Schwarz, K.M. Debatin, E. Kohne (University of
Ulm,
Ulm, Germany) |
| 11:45 - 12:00 |
DARBEPOETIN ALFA; SAFETY
AND LONG-TERM SURVIVAL DATA FROM 2 LARGE RANDOMISED PHASE 3
STUDIES
H. Hedenus, G. Rossi, L. Hendricks, J. Vansteenkiste (Sundsvall
Hospital, Sundsvall, Sweden) |
| 12:00 - 12:15 |
CARDIAC OUTPUT IN REGULARLY
TRANSFUSED PATIENTS WITH BETA-THALASSEMIA
D. Farmakis, F. Karabatsos, J. Joussef, S. Deftereos, A. Polonifi,
M. Karagiorga, A. Aessopos (University of Athens Medical School,
Athens, Greece) |
| 12:15 - 12:30 |
MUTATIONS OF HEMOJUVELIN
AND HEPCIDIN IN JUVENILE HEMOCHROMATOSIS
C. Camaschella, C. Lanzara, F. Daraio, M. Cazzola, A. Piperno,
T.M. Cox, G. Porto, S. Rivard, A. Roetto, F. Alberti (University
of Torino, Orbassano, Torino, Italy) |
| 12:30 - 12:45 |
EXPRESSION OF THE MOUSE ORTHOLOG
OF HEMOJUVELIN GENE DURING IRON OVERLOAD, INCREASED ERYTHROPOIESIS
AND FETAL LIVER DEVELOPMENT
J. Krijt, K-T. Chang, M. Vokurka, E. Necas (Charles University,
1st Medical Faculty, Prague, Czech Republic) |
|
SIMULTANEOUS SESSION
11:30 - 12:45, Room B (Geneva Palexpo)
| Chairs: |
J. Duyster (Technical University of Munich, Munich,
Germany)
R. Clark (Royal Liverpool University Hospital, Liverpool, United
Kingdom) |
| 11:30 - 11:42 |
IMATINIB MODULATES
ITS OWN UPTAKE AND EFFLUX EARLY IN THE TREATMENT OF CHRONIC
MYELOID LEUKAEMIA, VIA UPREGULATION OF THE TRANSPORTERS HOCT1
AND MDR1
L. Wang, J. Thomas, M. Pirmohamed, R.E. Clark (Royal Liverpool
University Hospital, Liverpool, United Kingdom) |
| 11:42 - 11:54 |
ABL MUTATIONS DETECTED BY
A NOVEL D-HPLC-BASED ASSAY IN LATE-CHRONIC PHASE CHRONIC MYELOID
LEUKEMIA PATIENTS RESISTANT TO IMATINIB ARE STRONGLY ASSOCIATED
TO SUBSEQUENT PROGRESSION TO BLAST CRISIS
S. Soverini, G. Rosti, M. Amabile, A. Poerio, S. Bassi, E. Trabacchi,
B. Izzo, M. Fava, F. Pane, G. Saglio, D. Alberti, M. Baccarani,
G. Martinelli (Institute of Hematology "Seràgnoli",
Bologna, Italy) |
| 11:54 - 12:06 |
INVOLVEMENT OF T-CELL PROTEIN
TYROSINE PHOSPHATASE (TC-PTP) IN THE RESISTANCE TO STI571 THROUGH
DOWN-STREAM SIGNALS OF BCR-ABL IN CML CELLS
T. Shimizu, Y. Miyakawa, S. Iwata, A. Kuribara, T. Tiganis,
C. Morimoto,
Y. Ikeda, M. Kizaki (Keio University School of Medicine, Tokyo,
Japan) |
| 12:06 - 12:18 |
MOLECULAR MONITORING OF CHRONIC
PHASE CML PATIENTS ENTERED IN THE INTERNATIONAL PROSPECTIVE
STUDY (IRIS) COMPARING IMATINIB (IM) AND INTERFERON/CYTARABINE
(IFN/ARA-C)
J.M. Goldman, J.P. Radich, J. Kaeda, I. Gathmann, C. So, S.
Branford, A. Hochhaus, A.E. Bolton, S. Silberman, T.P. Hughes
(Imperial College/ Hammersmith Hospital, London, United Kingdom) |
| 12:18 - 12:30 |
A RISE IN BCR-ABL TRANSCRIPT
LEVEL OF MORE THAN 2-FOLD IN IMATINIB-TREATED CHRONIC MYELOID
LEUKEMIA IDENTIFIES PATIENTS WITH BCR-ABL KINASE DOMAIN MUTATIONS
S. Branford, Z. Rudzki, A. Grigg, K. Taylor, J.F. Seymour, S.
Durrant, P. Browett, A.P. Schwarer, C. Arthur, J. Catalano,
M. Leahy, R. Filshie, K. Bradstock, R. Herrmann, K. Lynch, T.P.
Hughes (IMVS, Adelaide, Australia) |
| 12:30 - 12:42 |
PHASE-II STUDY OF HIGH-DOSE
IMATINIB IN PATIENTS WITH CHRONIC IDIOPATHIC MYELOFIBROSIS;
MODEST ACTIVITY, BUT ESTABLISHMENT OF THE UTILITY OF F-18 FLUOROTHYMIDINE
PET SCANNING IN DISEASE ASSESSMENT
J.F. Seymour, R. Hicks, P. Roselt, D.A. Westerman, H.M. Prince,
M.M. Wolf, E.H. Januszewicz, J. Davison, Z. Nikolova, S. Dimitrijevic,
G. McArthur (Peter MacCallum Cancer Centre, East Melbourne,
Australia) |
| 12:42 - 12:45 |
| DISCUSSION |
|
|
SIMULTANEOUS SESSION
11:30 - 12:45, Room C (Geneva Palexpo)
| Chairs: |
M. Dimopoulos (University of Athens School of
Medicine, Athens, Greece)
M. Boccadoro (Azienda S.G. Battista, Turin, Italy) |
| 11:30 - 11:42 |
ORAL MELPHALAN,
PRENDNISONE AND THALIDOMIDE FOR PREVIOUSLY UNTREATED MYELOMA
PATIENTS
A. Palumbo, A. Bertola, P. Musto, T. Caravita, V. Callea, M.
Nunzi, L. Catalano, V. De Stefano, P. Niscola, M. Grasso, P.
Falco, F. Cavallo, C. Cangialosi, S. Bringhen, M. Boccadoro
(Azienda Ospedaliera S. Giovanni Battista, Turin, Italy) |
| 11:42 - 11:54 |
THERAPY OF MULTIPLE MYELOMA
PATIENTS WITH DISSEASE PROGRESSION AFTER AUTOLOGOUS STEM CELL
TRANSPLANTATION, IN THE ERA OF THALIDOMIDE AND REDUCED INTENSITY
ALLOGENEIC STEM CELL TRANSPLANTATION
H. Hardan, A. Kneller, A. Shimoni, M. Berkowicz, A. Avigdor,
M. Yeshurun, I. Davidowich, P. Raanani, N. Shemtov, I. Ben Bassat,
A. Nagler (Sheba medical center, Tel-Hashomer, Israel) |
| 11:54 - 12:06 |
MULTIPLE MYELOMA: POPULATION
BASED RELATIVE SURVIVAL IN SWEDEN 1973-2001
S.Y. Kristinsson, O. Landgren, P. Dickman, A Rangert, M. Björkholm
(Karolinska University Hospital, Stockholm, Sweden) |
| 12:06 - 12:18 |
SURVIVAL, DURATION OF RESPONSE,
AND TIME TO PROGRESSION WITH BORTEZOMIB IN PATIENTS WITH RELAPSED
AND REFRACTORY MULTIPLE MYELOMA: AN UPDATE WITH ADDITIONAL FOLLOW-UP
P.G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath,
D. Irwin, S.V. Rajkumar, G. Srkalovic, M. Alsina, R. Alexanian,
D. Siegel, R. Orlowski, D. Kuter, T. Hideshima, D.L. Esseltine,
K.C. Anderson (Dana-Farber Cancer Institute, Boston, USA) |
| 12:18 - 12:30 |
BORTEZOMIB VERSUS DEXAMETHASONE
FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA:
A RANDOMIZED PHASE 3 TRIAL. THE APEX STUDY GROUP.
P. Richardson, P. Sonneveld, M.W. Schuster, D. Irwin, E.A. Stadtmauer,
T. Facon, W.S. Dalton, J-L. Harousseau, J.F. San Miguel, K.C.
Anderson (Dana-Farber Cancer Institute, Boston, USA) |
| 12:30 - 12:42 |
THE USE OF BORTEZOMIB (VELCADE®)
IN PATIENTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA
S. Jagannath, B.G.M. Durie, H. Wolf, E. Camacho, D. Irwin, J.
Lutzky, N. McKinley, E. Gabayan, J. Crowley, D. Schenkein (Salick
Health Care Research Network, New York, USA) |
| 12:42 - 12:45 |
| DISCUSSION |
|
SIMULTANEOUS
SESSION
11:30 - 12:45, Le Jura (Geneva Palexpo)
| Chairs: |
I. Pabinger (Medical Clinic I, Vienna, Austria)
J. Batlle (University Hospital Juan Canalejo, A Coruna, Spain) |
| 11:30 - 11:42 |
A NEW FAMILY
WITH PREKALLIKREIN (PK) DEFICIENCY CAUSED BY TWO MISSENSE MUTATIONS
(G104R,N124S) IN THE APPLE DOMAIN 2 OF PK HEAVY CHAIN (PK SEKI).
F. Maruyama, I. Katsuda, K. Ezaki, T. Sawamura, Y. Ichihara
(Fujita Health University Hospital, Toyoake, Japan) |
| 11:42 - 11:54 |
ITP AND HELICOBACTER PYLORI
NO INCREASED INFECTION PREVALENCE AND POOR PLATELET RESPONSE
TO ERADICATION THERAPY
H. Cherif, J. Khoshkar, R. Hast, L . Stenke, P.M. Hellström
(Karolinska Institute, Stockholm, Sweden) |
| 11:54 - 12:06 |
THROMBOPROPHYLAXIS WITH FONDAPARINUX
IN ACUTELY ILL MEDICAL PATIENTS AGED 75 YEARS OR MORE
A.T. Cohen, Artemis (Guy’s, King’s and St. Thomas’
School of M, London, United Kingdom) |
| 12.06 - 12:18 |
HAPTOGLOBIN PHENOTYPES AND
THE RISK FOR IDIOPATHIC VENOUS THROMBOEMBOLISM
R. Vormittag, T. Vukovich, I. Pabinger (University Hospital
Vienna, Wien, Austria) |
| 12:18 - 12:30 |
THE ESCHQOL STUDY: PILOT
TESTING RESULTS CONCERNING CLINICAL OUTCOMES IN HAEMOPHILIA
CARE IN EUROPE
A. Gringeri, S. Von Mackensen, K. Berger, M. Bullinger, P. Giangrande,
R. Ljung, L.G. Mantovani, L. Nemes, M. Serban, W. Schramm (University
of Milan, Milan, Italy) |
| 12:30 - 12:42 |
THE ESCHQOL STUDY: PILOT
TESTING RESULTS CONCERNING HEALTH CARE NEEDS IN HAEMOPHILIA
TREATMENT
S. Von Mackensen, K. Berger, P. Giangrande, A. Gringeri, R.
Ljung, L.G. Mantovani, L. Nemes, M. Serban, W. Schramm (University
Hospital Eppendorf, Hamburg, Germany) |
| 12:42 - 12:45 |
| DISCUSSION |
|
|
SIMULTANEOUS SESSION
11:30 - 12:45, Room D (Geneva Palexpo)
| Chairs: |
O. Ottmann (University of Frankfurt, Frankfurt,
Germany)
C. Thiede (Universitätsklinikum Carl Gustav Carus, Dresden,
Germany) |
| 11:30 - 11:45 |
SCINDERIN EXPRESSION
IN MEGAKARYOBLASTIC LEUKEMIA CELLS INDUCES DIFFERENTIATION,
RELEASE OF PLATELET-LIKE PARTICLES AND INHIBITS PROLIFERATION
AND TUMORIGENESIS
J-M. Trifaro, T. Lejen, R. Zunino, M.I. Romero-Benitez, B. Kuchuk-Sigal,
N.C. Brandan (Univ. of Ottawa, Ottawa On, Canada) |
| 11:45 - 12:00 |
MUTATIONS OF CEBPA, FLT3
AND RAS IN PATIENTS WITH DE NOVO ADULT LEUKEMIA: A STUDY FROM
THE ACUTE LEUKEMIA FRENCH ASSOCIATION (ALFA)
V. Coiteux, P. Huyghe, C. Sagot, H. Leroy, S. De Botton, N.
Boissel, M. Elhamri, I. Tigaud, J.M. Cayuela, C. Bastard, P.
Fenaux, H. Dombret, C. Preudhomme (CHU, Lille, France) |
| 12:00 - 12:15 |
IN VITRO ACTIVITY OF THE
FLT3-INHIBITOR SU5614 AND STANDARD CYTOTOXIC AGENTS IN TUMOUR
CELLS FROM PATIENTS WITH WILD TYPE AND MUTATED FLT3 ACUTE MYELOID
LEUKEMIA
A. Aleskog, M. Höglund, R. Larsson, M. Hermansson, E. Lindhagen
(University Hospital, Uppsala, Uppsala, Sweden) |
| 12:15 - 12:30 |
MOLECULAR THERAPY OF AML:
A NEW AND RAPID METHOD TO CHARACTERIZE NOVEL GENETIC VARIANTS
IN FLT3 GENE
G. Martinelli, M. Bianchini, E. Ottaviani, T. Grafone, B. Giannini,
S. Soverini, C. Terragna, M. Rondoni, P.P. Piccaluga, M. Malagola,
M. Baccarani (Inst. of Hematology and Medical Oncology, Bologna,
Italy) |
| 12:30 - 12:45 |
MICROARRAY TRANSCRIPT PROFILING
DISTINGUISHES THE TRANSIENT FROM THE ACUTE TYPE OF MEGAKARYOBLASTIC
LEUKAEMIA (M7) IN DOWN SYNDROME, REVEALING A PROGRESSION-SPECIFIC
DISCRIMINATING MARKER
C. Mulligan, S. McElwaine, J. Groet, M. Spinelli, A. Rinaldi,
G. Denyer, A.A. Mensah, S. Cavani, C. Baldo, F. Dagna-Bricarelli,
I. Hann, G. Basso, F.E. Cotter, D. Nizetic (Barts and The London
Medical School, London, United Kingdom) |
|
HEMATOLOGY-IN-FOCUS
SESSION
10.15 - 11.00, Room A (Geneva Palexpo)
| Chair: |
C. Negrier (Hôpital Edouard Herriot, Lyon,
France) |
 |
CLOTTING FACTOR CONCENTRATES
IN THE MANAGEMENT OF LIFE-THREATENING HAEMORRAGE
Ph. De Moerloose (Unite de Hemostase, Geneva, Switzerland) |
| |
ACQUIRED HAEMOPHILIA AND VON WILLEBRANDS
DISEASE
I. Pabinger (Medical Clinic I, Vienna, Austria) |
HEMATOLOGY-IN-FOCUS SESSION
10.15 - 11.00, Room B (Geneva Palexpo)
| Chair: |
F. Guilhot (University Hospital la Milétine,
Poitiers, France) |
| |
COMBINATION THERAPIES
J. Apperley (Hammersmith Hospital, London, United Kingdom) |
| |
MOLECULAR MONITORING
A. Hochhaus (Klinikum Mannheim, Mannheim, Germany) |
HEMATOLOGY-IN-FOCUS SESSION
10.15 - 11.00, Room C (Geneva Palexpo)
| Chair: |
B. Chapuis (University Hospital Geneva, Geneva,
Switzerland) |
| |
ALGORHYTHMS FOR TRANSPLANTATION:
AUTO-ALLO-HAPLOCORD- MINI-MIDI-MAXI IN ALL
D. Hoelzer (Johan Wolfgang Goethe University, Frankfurt, Germany) |
| |
TRANSPLANTATION IN AML: OPTIMIZING INDICATION,
CONDITIONING REGIMEN, STEM CELL SOURCE AND STEM CELL DONOR
J. Sierra (Hospital de la Santa Creu I Sant Pau, Barcelona,
Spain) |
|
|
HEMATOLOGY-IN-FOCUS
SESSION
10.15 - 11.00, Room Le Jura (Geneva Palexpo)
| Chair: |
G. Gahrton (Karolinska University Hospital, Stockholm,
Sweden) |
| |
MYELOMA
J.F. San Miguel (Hospital Universitario de Salamanca, Salamanca,
Spain) |
| |
CML - MOLECULAR BASIS OF THERAPY
J.M. Goldman (Hammersmith Hospital, London, United Kingdom) |
HEMATOLOGY-IN-FOCUS SESSION
10.15 - 11.00, Room D (Geneva Palexpo)
| Chair: |
J.D. Tissot (Unité de Medecine Transfusionelle,
Lausanne, Switzerland) |
| |
IMMUNOHEMATOLOGICAL CHARACTERISTICS
OF NON-CAUCASIANS
F. Noizat-Pirenne (EFS Hôpital Henri mondor, Créteil,
France) |
| |
THE RHESUS SYSTEM: OPPORTUNITIES AND REMAINING
MYSTERIES
W.A. Flegel (Universitätsklinikum Ulm, Ulm, Germany) |
HEMATOLOGY-IN-FOCUS SESSION
10.15 - 11.00, Room H (Geneva Palexpo)
| Chair: |
J.J.M. Van Dongen (Erasmus Medical Center, Rotterdam,
The Netherlands) |
| |
THE VDJ RECOMBINASE SYSTEM:
CURRENT KNOWLEDGE
J.P. De Villartey (Hospital Necker Enfants, Paris, France) |
| |
VDJ RECOMBINASE-RELATED ONCOGENIC EVENTS
AND CLASSIFICATION OF LEUKEMIAS
A.W. Langerak (Erasmus Medical Center, Rotterdam, The Netherlands)
|
|
EHA EDUCATION FORUM
12.45-14.00, Room Le Mont-Blanc/Le Cervin (Geneva Palexpo)
EHA has a strong interest in educational and professional issues of
concern to European hematologists. An update on the Education Committee’s
activities and projects will be presented. These will include an interactive
demonstration of EHA’s new self-learning tool: European Hematology
Association Training on-line.
LUNCH DEBATE
13.00 - 14.00, Room A (Geneva Palexpo)
| Chair: |
A. Urbano-Ispizua (University of Barcelona, Barcelona,
Spain) |
| |
YES
G.J. Mufti (GKT School of Medicine, London, United Kingdom) |
| |
NO
T. de Witte (University Medical Centre St.Radboud, Nijmegen,
The Netherlands) |
LUNCH DEBATE
13.00 - 14.00, Room Le Jura (Geneva Palexpo)
| Chair: |
A. Ganser (Medizinische Hochschule Hannover,
Hannover, Germany) |
| |
YES
P. Sonneveld (Erasmus University Medical Center, Rotterdam,
The Netherlands) |
| |
NO
T. Büchner (University of Münster, Münster, Germany) |
|
|
LUNCH DEBATE
13.00 - 14.00, Room D (Geneva Palexpo)
| Chairs: |
Chair: C. Schoch (Laboratory for Leukemia Diagnostics,
Munich, Germany) |
| |
YES
T. Haferlach (University Hospital München-Grosshadern,
München,
Germany) |
| |
NO
J.J.M. Van Dongen (Erasmus University Medical Center, Rotterdam,
The Netherlands) |
EHA BUSINESS MEETING
14:00 – 14:30, Room D (Geneva Palexpo)
PLENARY
SESSION 1
14.30 - 15.30, Plenary room (A+B+C, Geneva Palexpo)
| Chairs: |
J. San Miguel (University Hospital Salamanca,
Salamanca, Spain)
E. Hellström-Lindberg (Karolinska Institute, Huddinge,
Sweden) |
| |
SYSTEMS BIOLOGY: THE CELL’S
NETWORK ARCHITECTURE, AND WHAT CAN WE LEARN FROM IT
A-L. Barabasi (University of Notre Dame, Notre Dame, IN, USA) |
| |
NEW DRUG DEVELOPMENT
P. Workman (Institute of Cancer Research, Sutton, United Kingdom) |
|
PRESIDENTIAL SYMPOSIUM
- 6 BEST ABSTRACTS
15:45 - 17:15, Plenary room (A+B+C, Geneva Palexpo)
| Chair: |
A. Gratwohl (Kantonsspital Basel, Basel, Switzerland)
E. Montserrat (Hospital Clinic Barcelona, Barcelona, Spain) |
| 15:45 - 16:00 |
317 AML1-EVI-1
KNOCK-IN MICE SHOW MORE DYSPLASTIC FETAL HEMATOPOIESIS THAN
AML1-ETO KNOCK-IN MICE
K. Mitani, K. Maki, T. Yamagata, T. Asai, M. Ichikawa, H. Hirai
(Dokkyo University School of Medicine, Tochigi, Japan) |
| 16:00 - 16:15 |
RE-IIBP IS THE ONLY UNIQUELY
DYSREGULATED AND POTENTIALLY FUNCTIONAL TARGET GENE OF T(4;14)(P16;Q32)
MYELOMA
J. Keats, C.A. Maxwell, M. Ye, T. Tiffinger, M.J. Mant, T. Reiman,
A.R. Belch, L.M. Pilarski (University of Alberta, Edmonton,
Canada) |
| 16:15 - 16:30 |
MUTATIONS IN THE ATP-BINDING
POCKET OF FLT3 CONFERRING RESISTANCE TO TYROSINE KINASE INHIBITORS:
IMPLICATIONS FOR MOLECULARLY TARGETED THERAPY FOR ACUTE MYELOID
LEUKEMIA
J. Cools, D. Fabbro, P. Furet, N. Mentens, J.D. Griffin, P.
Marynen, D.G. Gilliland (University of Leuven - VIB, Leuven,
Belgium) |
| 16:30 - 16:45 |
ECULIZUMAB, A C5 COMPLEMENT-BLOCKING
ANTIBODY, CONTROLS HAEMOLYSIS IN PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA
(PNH) WITH RESPONSES MAINTAINED
OVER A PROLONGED PERIOD OF THERAPY
A. Sah, C. Hall, J. Marsh, D. Elebute, S.A. Rollins, C.F. Mojcik,
R.P. Rother, P. Hillmen (Leeds General Infirmary, Leeds, United
Kingdom) |
| 16:45 - 17:00 |
THE HIGH PREVALENCE OF CHLAMYDIA
PSITTACI INFECTION IN OCULAR ADNEXAL LYMPHOMAS (OAL) PROVIDES
THE RATIONALE FOR THE USE OF ANTIBIOTICS AS A POTENTIAL THERAPEUTIC
STRATEGY IN THESE PATIENTS
A.J.M. Ferreri, M. Guidoboni, M. Ponzoni, C. De Conciliis, S.
Dell’Oro, K. Fleishhauer, L. Caggiari, A.A. Lettini, R.
Ieri, M. Freschi, C. Doglioni, E. Villa, M. Boiocchi, R. Dolcetti
(San Raffaele H Scientific Institute,
Milan, Italy) |
|
|
| 17:00 - 17:15 |
A RANDOMIZED
PHASE II STUDY COMPARING IMATINIB WITH CHEMOTHERAPY AS INDUCTION
THERAPY IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA-POSITIVE
ACUTE LYMPHOID LEUKEMIAS (PH+ALL)
O.G. Ottmann, B. Wassmann, N. Gökbuget, A. Binckebanck,
H. Pfeifer, P. Brück, R. Reutzel, A. Giagounidis, M. Planker,
K. Troll, M. Stelljes, M. Schmalzing, H. Kohlhammer, J. Perz,
S. Haas, J. Beck, H. Gschaidmeier, D. Hoelzer (Johan Wolfgang
Goethe University, Frankfurt, Germany) |
MPD SYMPOSIUM
18:30 – 20:00, Room D (Geneva Palexpo)
| Chair: |
G. Finazzi (Bergamo, Italy) and M. Griesshammer
(Ulm, Germany) |
| |
18:30-18:45 |
| |
PATHOLOGICAL AND CLINICAL
FEATURES ARE OF DIAGNOSTIC AND PROGNOSTIC IMPACT IN PH-NEGATIVE
MPDS WITH THROMBOCYTHEMIA
H.M. Kvasnicka (Cologne, Germany) |
| |
18:45-19:00 |
| |
ACUTE MALIGNANT PANMYELOSIS WITH MYELOFIBROSIS:
A REPORT OF 46 CASES
A. Schmitt-Graeff (Freiburg, Germany) |
| |
19:00-19:15 |
|
THE LONG TERM HYDROXYUREA/PIPOBROMAN TOXICITY
DATA IN THE FRENCH ET/PV PROTOCOLS AS A STRONG RATIONALE FOR
INTERFERON OR ANAGRELIDE STUDIES
J.J. Kiladjian (Paris, France) |
| |
19:15-19:30 |
|
UPDATE ON THE USE OF ANAGRELIDE IN THROMBOCYTHEMIA
OF VARIOUS MPDS
G. Birgegard (Uppsala, Sweden) |
| |
19:30-19:45 |
|
THE IMPACT OF CLINICOPATHOLOGICAL STUDIES
ON RISK STRATIFICATION, STAGING, MANAGEMENT AND SURVIVAL IN
ET, PV AND EARLY IMF
J.J. Michiels (Antwerp, Belgium) |
| |
19:45-20:00 |
|
CONCLUSIONS, FUTURE STUDIES AND PERSPECTIVES
M. Griesshammer and G. Finazzi |
|
MEETING ORGANIZED BY THE GROUPE
D’ETUDES DES LYMPHOMES DE L’ADULTE
18:30 – 20:30, Room H (Geneva Palexpo)
During this symposium, speakers from the GELA will explain how therapeutic
strategies and clinico-biological programs developed by the group
have evolved and which new directions are envisaged. A round table
including colleagues of other groups will close the meeting.
SYMPOSIUM OF THE EUROPEAN WORKING GROUP FOR
ADULT ALL
18:30 – 20:30, Room E (Geneva Palexpo)
| Chair: |
T. Kovacsovics and D. Hoelzer |
| |
EORTC ALL-4 STUDY
B. Labar (EORTC) |
| |
PILOT STUDY GRAAL 2003
F. Huguet (GRAALL) |
|
GENOMIC ANALYSIS IN GIMEMA TRIALS
R. Foà (GIMEMA) |
|
RISK STRATIFIED GMALL STUDY 07/2003 HOVON
D. Hoelzer (GMALL) |
|
SUBGROUP ANALYSIS OF AUTOLOGOUS SCT
A. Dekker (HOVON) |
|
MRD ORIENTED STUDY NILG-9
R. Bassan (NILG) |
|
TREATMENT OF PH+ ALL WITH AND WITHOUT
IMATINIB UPFRONT
J. Ribera (PETHEMA) |
|
UPDATE ON UKALL12/ECOG 2993 & FUTURE
PLANS
T. Goldstone (MRC) |
|
PSYCHOSOCIAL SESSION
18:30 – 20:30, Room I (Geneva Palexpo)
| Chair: |
S. v. Mackensen (Germany) and L. Massimo (Italy) |
| |
18.30 – 18.45 |
| |
INTRODUCTION
S. v. Mackensen (Germany) and L. Massimo (Genova, Italy) |
| |
18.45 – 19.00 |
| |
PRELIMINARY RESULTS OF THE DEVELOPMENT
OF A QUALITY OF LIFE QUESTIONNAIRE FOR ADULT PATIENTS WITH HAEMOPHILIA
(HAEM-A-QOL)
S. v. Mackensen (Hamburg, Germany) |
| |
19.00 – 19.15 |
|
DEVELOPMENT AND PILOT TESTING OF THE HEMOFILIA-QOL.
A NEW DISEASE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE TO ADULTS
LIVING WITH HEMOPHILIA
E. Remor (Madrid, Spain) |
| |
19.15 – 19.30 |
|
INFORMED CONSENT FOR RANDOMIZATION IN
PEDIATRIC HEMATOLOGY AND ONCOLOGY
L. Massimo (Genova, Italy) |
| |
19.30 – 19.45 |
|
DRAWINGS, THE UNIVERSAL LANGUAGE OF CHILDREN.
THE EXPERIENCE WITHIN A PEDIATRIC HEMATOLOGY AND ONCOLOGY UNIT
D. Zarri (Genova, Italy) |
| |
19.45 – 20.00 |
|
THE SCHOOL IN HOSPITALS FOR CHILDREN AFFECTED
BY LEUKAEMIA
F. Beltrame (Monza, Italy) |
| |
20.00 – 20.15 |
|
QUALITY OF LIFE FROM THE PHYSICIAN’S
PERSPECTIVE
A. Gringeri (Milan, Italy) |
| |
20.15 – 20.30 |
|
CONCLUSION OF THE SESSION
S. v. Mackensen (Hamburg, Germany) |
|
SECOND SCIENTIFIC WORKSHOP OF
THE EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC)
18:30 – 20:30, Room Le Jura (Geneva Palexpo)
| Organizers: |
D. Catovsky, G. Dighiero, M. Hallek, E. Montserrat |
| |
18:30 – 18:45 |
| |
IMMUNOBIOLOGY OF CLL
F. Caligaris-Cappio (Italy) |
| |
18:45 – 19:00 |
| |
GENETIC SUBTYPES AND PROGNOSIS IN CLL
H. Döhner (Germany) |
| |
19:00 – 19:15 |
|
CHEMOTHERAPY WITH PURINE ANALOGS –
WHAT IS THEIR ROLE IN 2004?
M. Kasznicki (Poland) |
| |
19:15 – 19:30 |
|
CHEMOIMMUNOTHERAPY IN CLL – UP DATE
2004
P. Hillmen (United Kingdom) |
| |
19.30 – 19:45 |
|
ROLE OF HEMATOPOIETIC PROGENITOR CELL
TRANSPLANTATION IN 2004?
M. Michallet (France) |
|
MEETING ORGANIZED BY THE EUROPEAN
LEUKEMIANET
18:30 – 20:30, Salon 13 (Villa Sarasin, 1st floor)
| Chair: |
M. Baccarani (University of Bologna, Insttuto
di Ematologia e Oncologia Medica, Bologna, Italy) |
MEETING ORGANIZED BY THE EUROPEAN LEUKEMIANET
18:30 – 20:30, Salon 5 (Villa Sarasin, Ground floor)
| Chairs: |
T. Barbui (Ospedali Riuniti Bergamo, Bergamo,
Italy)
G. Barosi (Policlinico San Matteo, Pavia, Italy)
G. Finazzi (Ospedali Riuniti Bergamo, Bergamo, Italy) |
MEETING ORGANIZED BY THE EUROPEAN LEUKEMIANET
18:30 – 20:30, Salon 2 (Villa Sarasin, Ground floor)
| Chair: |
D. Grimwade (King’s College, London, United
Kingdom) |
MEETING ORGANIZED BY THE EUROPEAN LEUKEMIANET
18:30 – 20:30, Salon 11 (Villa Sarasin, 1st floor)
| Chair: |
H. Einsele (Universitätsklinikum Tübingen,
Tübingen, Germany) |
|
POSTER SESSION II
17:15 - 18:45, Hall I (Geneva Palexpo)
| |
Lymphoma: Clinical aspects |
| |
Lymphoma: Treatment with chemotherapy |
| |
Multiple Myeloma: Conventional treatment |
|
Multiple Myeloma: New treatments |
|
ALL: Therapy & MRD |
|
CLL: Biology |
|
AML: Biology |
|
Chronic Myeloproliferative disorders |
|
Stem cell transplantation – Allogeneic |
|
Myelodysplastic syndromes |
|
Bleeding disorders |
|
Vascular Biology |
|
Platelet disorders |
|
Cost effectiveness & Quality of life |
|
Drug resistance / Drug pharmacology |
|
Signalling & Transcription |
|
Anemia - Growth factors |
|
Iron / Bone marrow failure |
|
Immunophenotyping / Gene therapy |
NEW THIS YEAR: “POSTER-WALKS”
 |
Unique full-three-day display
of all posters |
| |
Poster walks will be organized during the
official poster sessions. Authors are requested to be
present at the first poster of their poster session, at
the beginning of the presentation time, to attend the
“Poster-walks”. During these walks, an expert
in the field will discuss posters in the same poster session.
Moderators and poster authors will present and discuss
each poster in a certain session, together
with interested Congress participants. |
|
HE HEPATITIS
C VIRUS INCIDENCE IN NON-HODGKIN’S LYMPHOMAS PATIENTS
G. Gaman, A. Gaman, C. Besliu (University of Medicine and Pharmacy,
Craiova, Romania) |
THE USE OF 18FDG-PET/CT FOR
EVALUATION OF NEUROLYMPHOMATOSIS
O. Goor, F. Bokstein, Y. Goor, E. Even-Sapir, U. Metser (Tel
Aviv Sourasky Medical Center, Tel Aviv, Israel) |
CENTRAL NERVOUS SYSTEM (CNS)
INVOLVEMENT IN MANTLE CELL LYMPHOMA (MCL)
A. Ferrer, F. Bosch, A. Lopez-Guillermo, M. Rozman, J.L. Aguilar,
E. Campo,
E. Montserrat (Hospital Clinic, Barcelona, Spain) |
|
|
RESULT OF A MULTICENTRE
CASE-CONTROL STUDY ON HEPATITIS B VIRUS (HBV) AND LYMPHOMA
A. Pulsoni, E. Bianco, P. Chionne, A. Candido, R. Cotichini,
A. De Renzo, E. Iannitto, E. Madonna, B. Martino, M. Montanaro,
P. Musto, R. Nieddu, M. Quaresima, E. Spada, M. Rapicetta, A.
Mele (Ematologia, La Spienza University, Rome, Roma, Italy)
|
SERIAL PRE-TRANSPLANTATION
FDG-PET SCANNING TO PREDICT OUTCOME IN CHEMOSENSITIVE RELAPSED
LYMPHOMA
B.W. Schot, C. Verhoogt, G.W. van Imhoff, J. Pruim, W. Sluiter,
E. Vellenga (University Hospital Groningen, Groningen, The Netherlands) |
DIFFUSE SKELETAL UPTAKE OF
GA-67 IN HODGKIN’S DISEASE WITHOUT BONE MARROW INVOLVEMENT
P. Stark, A. Steinmetz, H. Bernstine, S. Morgenstern, M. Shaklai,
R. Hardoff (Institute of Hematology, Petah Tikva, Israel) |
CLINICAL FEATURES AND INCIDENCE
OF HCV INFECTION AND SOLID TUMORS IN 58 CASES OF NON-GASTRIC
MARGINAL ZONE B-CELL LYMPHOMA OF MALT
L.A. Arcaini, S. Burcheri, E. Orlandi, E. Brusamolino, F. Passamonti,
C. Astori, N. Colombo, P. Bertazzoni, M. Paulli, M. Boveri,
C. Pascutto, M. Lazzarino (Division of Hematology, Pavia, Italy) |
HODGKIN’S DISEASE IN
CHILDHOOD: A 20-YEAR EXPERIENCE AT A SINGLE CENTER
A.G. Pourtsidis, M. Baka, D. Bouhoutsou, D. Varvoutsi, D. Doganis,
M. Synodinou, H. Kosmidi (“Aglaia kyriakou” children’s
hospital, Athens, Greece) |
DELIVERY OF PLANNED CHEMOTHERAPY
DOSE ON TIME FOR PATIENTS WITH EARLY STAGE HODGKIN’S LYMPHOMA
(ESHL): PRELIMINARY RESULTS OF AN ALLG-TROG STUDY
A. Wirth, A. Grigg, M. Wolf, S. Davis, M. Hertzberg, D. Joseph,
C. Johnson, L. Weih (Peter MacCallum Cancer Centre, East Melbourne,
Australia) |
PRIMARY TESTICULAR LYMPHOMA:
A CLINICOPATHOLOGIC MULTICENTRIC STUDY OF 58 CASES
I. Vásová, L. Boudová, D. Minarikova, O.
Hes, K. Cerná, R. Curik, P. Fabian, M. Navratil, F. Fakan,
M. Michal (Masaryk University Hospital Brno, Brno, Czech Republic) |
EPIDEMIOLOGY OF NON-HODGKIN’S
LYMPHOMA (NHL): TRENDS, GEOGRAPHIC DISTRIBUTION AND ETIOLOGY
A.M.S. Müller, G. Ihorst, R. Mertelsmann, M. Engelhardt
(University of Freiburg, Freiburg, Germany) |
GA-67 UPTAKE: A PREDICTOR
OF ACTIVE MINIMALY RESIDUAL DISEASE AND CLINICAL OUTCOME IN
PATIENTS WITH DIFFUSE LARGE CELL LYMPHOMA
I. Sari, B. Eser, M. Kula, F. Altuntas, E. Mavili, M. Ozkan,
M. Cetin, A. Tutus, A. Unal (Erciyes University, Kayseri, Turkey) |
|
DEVELOPMENT AND
VALIDATION OF A CLINICAL PREDICTION RULE FOR BONE MARROW INVOLVEMENT
(BMI) IN PATIENTS WITH HODGKIN’S LYMPHOMA (HL)
T.P. Vassilakopoulos, M.K. Angelopoulou, N. Constantinou, T.
Karmiris, P. Repoussis,
P. Roussou, M.P. Siakantaris, P. Korkolopoulou, M-C. Kyrtsonis,
S.I. Kokoris, M.N. Dimopoulou, E. Variamis, E. Dimitriadou,
P. Panayiotidis, C. Kittas, G.A. Pangalis (University of Athens,
Athens, Greece) |
LYMPHOMA OF THE ORAL CAVITY.
TEN-YEAR EXPERIENCE OF A SINGLE HAEMATOLOGY UNIT
M.P. Siakantaris, T. Tzenou, T.P. Vassilakopoulos, M-C. Kyrtsonis,
M.K. Angelopoulou, M.N. Dimopoulou, S.I. Kokoris, E.M. Dimitriadou,
P. Korkolopoulou, E. Patsouris,
E. Variamis, G. Laskaris, G.A. Pangalis (University of Athens,
Athens, Greece) |
RISK OF NON-HODGKIN’S
LYMPHOMA AND HEPATITIS C VIRUS INFECTION
A. Uras, G. Piras, M. Monne, M. Murineddu, A. Palmas, A. Nieters,
P. Cocco, S. Collu, M.G. Ennas, M. Rais, P.F. Todde, E. Angelucci,
G. Massarelli, G. Broccia, A. Gabbas (Hematology Dept “San
Francesco” Hospital, Nuoro, Italy) |
CORRELATION BETWEEN CLINICAL,
HISTOLOGICAL, SKIN PCR DATA AND CLINICAL OUTCOME IN PATIENTS
WITH EARLY STAGE MYCOSIS FUNGOIDES TREATED WITH LOW DOSE INTERFERON
COMBINED WITH PUVA.
S. Rupoli, G. Goteri, S. Pulini, A. Tassetti, A.R. Scortechini,
S. Barulli, M. Giangiacomi, R. Ranaldi, A. Giacchetti, E. Grilli
Cicilioni, L. Bugatti, G. Ricotti, M. Simonacci,
M. Offidani, G. Fabris, P. Leoni (Politechnic University of
Marches, Ancona, Italy) |
BCL-2//IGH REARRANGED CELLS
IN THE BLOOD AND BONE MARROW OF PATIENTS WITH STAGE I/II FOLLICULAR
LYMPHOMA. POSSIBLE CLEARANCE AFTER LOCAL RADIOTHERAPY
A. Pulsoni, I. Della Starza, E. Cavalieri, N. Frattarelli, V.
Gianfelici, L. Grapulin,
M. Quaresima, R. Foà (University “La Sapienza”,
Rome, Italy) |
ROLE OF WHOLE-BODY POSITRON
EMISSION TOMOGRAPHY USING FLUORODEOXYGLUCOSE (FDG-PET) IN THE
EVALUATION OF RESIDUAL MASS IN HODGKIN’S DISEASE: A MONOCENTRIC
EXPERIENCE
E. Cavalieri, V. Gianfelici, A.P. Anselmo, N. Frattarelli, A.
Guerrisi, M.F. Osti,
M. Quaresima, A. Pulsoni (Ematologia Università “La
Sapienza”, Roma, Italy) |
THE COMBINED PET/CT SCANNER
- AN INVALUABLE AID IN THE MANAGEMENT OF COMPLEX LYMPHOMA PATIENTS
FROM NORTHERN IRELAND.
G.M. Benson, A.P. Shiels, J. Clarke, R.J.G. Cuthbert, M. Drake,
M. El-Agnaf, D. Hull,
P.J. Kettle, T.C.M. Morris (Belfast City Hospital, Bangor, Northern
Ireland) |
|
|
LYMPHOMAS IN
PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY: THE SINGLE CENTER
EXPERIENCE
M. Bouzani, M. Michael, L. Evliati, S. Delimbassi, I. Kakkas,
J. Apostolidis, M. Pagoni, T. Karmiris, M. Mpakiri, D. Rondogianni,
E. Nikiforakis (Evagelismos, Athens, Greece)
|
AVERAGE RELATIVE
DOSE AND DOSE-INTENSITY IN PATIENTS TREATED FOR DIFFUSE LARGE
B-CELL LYMPHOMA : A RETROSPECTIVE STUDY IN BELGIUM (1995-2000)
A. Bosly, D. Bron, A. Van Hoof, G. Verhoef (UCL Mont-Godinne,
Yvoir, Belgium) |
AN OUTPATIENT SALVAGE APPROACH
FOR NON-HODGKIN’S LYMPHOMA (NHL) AND HODGKIN’S LYMPHOMA
(HL) INCORPORATING RISK-FACTOR STRATIFICATION AND TREATMENT
ESCALATION
A. Spencer, V. Ganju, A. Grigg, M. Leahy, C. Underhill, J. Catalano,
C. Arthur (Alfred Hospital, Melbourne, Australia) |
AUTOLOGOUS TRANSPLANTATION
FOR AGGRESSIVE NONHODGKIN’S LYMPHOMA: 13 YEAR EXPERIENCE
AT A SINGLE INSTITUTION
C. Hosing, M.F. Munsell, G.J. Okoroji, J.D. McMannis, D. Couriel,
M. De Lima, S. Giralt, L. Fayad, B. Pro, A. Younes, R.E. Champlin,
I.F. Khouri (M.D. Anderson Cancer Center, Houston, TX, USA) |
HIGH EFFICACY OF BRIEF DURATION
HIGH INTENSITY MULTI AGENT CHEMOTHERAPY FOR TREATMENT OF IMMUNOCOMPETENT
ADULT PATIENTS WITH BURKITT’S AND BURKITT-LIKE NONHODGKIN’S
LYMPHOMAS
G.M.F. Aldawsari, N. Chaudhri, E. Sahovic, F.I. Al Mohareb,
F. Al Sharif, H. Al Zahrani, H. Al Omer, A. Al Shanqeeti, P.
Seth, I. El Hassan, M.D. Aljurf (KFSH and RC, Riyadh, Saudi
Arabia) |
LOW DOSE SINGLE SHOT 2-CHLORODEOXYADENOSINE (2-CDA)
IN PATIENTS WITH HAIRY CELL LEUKEMIA
R.Z. Zenhäusern, A. Von Rohr, K. Rufibach, M. Solenthaler,
S. Meyer-
Monard, A. Gratwohl, U. Hess, M. Bargetzi, T. Kovacsovic, L.
Leoncini,
A. Tobler (Inselspital, Bern, Switzerland) |
CHEMOTHERAPY-RELATED NEUTROPENIC
EVENTS IN PATIENTS WITH NON HODGKIN’S LYMPHOMA - A COMPARISON
OF TWO EUROPEAN AUDITS
A. Bosly, R. Pettengell, M. Constenla, C. Jackisch, R. Leonard,
R. Paridaens,
T.D. Szucs, M. Schwenkglenks (Cliniques Universitaires UCL,
Mont-godinne, Belgium) |
PEDIATRIC BURKITT LYMPHOMA
TREATED WITH LMB PROTOCOLS
C. Geraldes Santos, M. Brito, M. Benedito, L. Maricato, R. Batista,
G. Tamagnini (Hospital Pediátrico de Coimbra, Coimbra,
Portugal) |
|
TREATMENT OF
HIGH-RISK MEDIASTINAL DIFFUSE LARGE BCELL LYMPHOMA (DLBCL) WITH
MEGACHOP AND AUTOLOGOUS TRANSPLANT (ASCT)
R. Pytlik, K. Kubacková, P. Zák, M. Jankovská,
J. Pirnos, J. Pukyová, T. Papajík, D. Belada,
T. Kozák, H. Siffnerová, I. Vásová,
M. Hamouzová, M. Trnen´y (General University Hospital,
Prague, Czech Republic) |
A(E)BVD CHEMOTHERAPY (CT)
PLUS LOW DOSE INVOLVED FIELD RADIATION THERAPY (RT) FOR EARLY
CLINICAL STAGE HODGKIN’S LYMPHOMA (HL): THE EFFECT OF
RADIATION DOSE ON RELAPSE FREE SURVIVAL (RFS)
T.P. Vassilakopoulos, M.K. Angelopoulou, M.P. Siakantaris, M-C.
Kyrtsonis, F.N. Kontopidou, M.N. Dimopoulou, S.I. Kokoris, E.
Dimitriadou, P. Tsaftaridis, E. Variamis, H. Zambatis, T. Michalopoulos,
V.A. Boussiotis, P. Panayiotidis, G. Papavassiliou, G.A. Pangalis
(University of Athens, Athens, Greece) |
MANAGEMENT OF PRIMARY CUTANEOUS
T- AND B-CELL LYMPHOMA WITH INTERFERON ALPHA-2B (IFN-A). A SINGLE
CENTER EXPERIENCE
M.P. Siakantaris, M-C. Kyrtsonis, T. Tzenou, E.M. Dimitriadou,
M.N. Dimopoulou,
M.K. Angelopoulou, S.I. Kokoris, T.P. Vassilakopoulos, P. Korkolopoulou,
A. Giannakakis, E. Patsouris, A. Katsambas, G.A. Pangalis (University
of Athens, Athens, Greece) |
HIGH CLINICAL AND MOLECULAR
RESPONSE RATES WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND MITOXANTRONE
(FCM) IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED STAGE FOLLICULAR
LYMPHOMA (FL)
C. Moreno, A. López-Guillermo, S. Montoto, E. Domingo-Domènech,
J.M. Ribera,
A. Altés, C. Estany, J. Besalduch, L. Escoda, C. Pedro,
S. Gardella, A. Asensio,
A. Fernández-Sevilla, D. Colomer, E. Montserrat (GELCAB,
Barcelona, Spain) |
OUTCOME OF PATIENTS
WITH MULTIPLE MYELOMA AND HYPERTENSION TREATED WITH ANGIOTENSIN-I
CONVERTING ENZYME INHIBITORS AT THE TIME OF AUTOLOGOUS STEM
CELL TRANSPLANTATION
T. Buchler, M. Krejci, Z. Adam, R. Hajek, A. Svobodnik, J. Minarik,
J. Bacovsky,
V. Scudla, J. Mayer, J. Vorlicek (Masaryk University Hospital
Brno, Brno, Czech Republic) |
A PHASE I/II STUDY OF XCELLERATED
T CELLS AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
IN PATIENTS WITH MULTIPLE MYELOMA
R. Berenson, R. Vij, I.M. Borrello, R.A. Vescio, T.G. Martin,
D. Siegel, J.F. di Persio,
F. Janmohamed, K. Anderson, M. Bonyhadi, R.J. Berenson, M.W.
Frohlich (Oncotherapeutics, Los Angeles, USA) |
|
|
RECOMBINANT HUMAN
ERYTHROPOIETIN AND THE RISK OF THROMBOSIS OF MULTIPLE MYELOMA
PATIENTS RECEIVING THALIDOMIDE
M. Galli, F. Elice, C. Crippa, F. Scognamiglio, B. Comotti,
F. Rodeghiero, T. Barbui (Ospedali Riuniti, Bergamo, Italy) |
REMISSION STATUS AT FIRST
AUTOTRANSPLANT IS A PROGNOSTIC FACTOR OF BETTER SURVIVAL IN
MULTIPLE MYELOMA
C. Crippa, A.M. Barbui, T. Barbui, A. Rambaldi, M. Galli (Ospedali
Riuniti, Bergamo, Italy) |
THE COMBINED IN VITRO ACTIVITY
OF THALIDOMIDE AND ZOLEDRONIC ACID INDUCES NFKAPPAB-MEDIATED
ANTIPROLIFERATIVE EFFECTS ON MULTIPLE MYELOMA CELLS
P. Papadopoulos, M. Theodoropoulou, A. Maniatis, A. Mouzaki
(University of Patras, School of Medicine, Patras, Greece) |
AUTOLOGOUS STEM CELL TRANSPLANTATION
AS FIRST LINE AND SALVAGE TREATMENT FOR MULTIPLE MYELOMA: A
SINGLE CENTRE EXPERIENCE
F. Elice, A. Tosetto, R. Raimondi, R. Sartori, S. Roberti, A.
Piccin, F. Rodeghiero (San Bortolo Hospital, Vicenza, Italy) |
EARLY RESPONSE PREDICTS THALIDOMIDE
EFFICIENCY IN PATIENTS WITH ADVANCED MULTIPLE MYELOMA
A. Waage, P. Gimsing, G. Juliusson, I. Turesson, M. Hjorth,
J. Nielsen, S. Lenhoff,
J. Westin, F. Wisløff (St. Olavs University Hospital,
Trondheim, Norway) |
RESULTS OF AUTOLOGOUS TRANSPLANTATION
FOR MULTIPLE MYELOMA IN AUSTRIA. AN ANALYSIS BASED ON DATA FROM
THE AUSTRIAN STEM CELL (ASCT) REGISTRY
H. Ludwig, W. Linkesch, P. Kalhs, N. Zojer, O. Krieger, H. Greinix,
W. Hinterberger,
E. Pittermann, F. Bauer, J. Drach, H. Gisslinger, R. Greil,
G. Gastl (Wihelminen Hospital, Vienna, Austria) |
THE COMBINATION OF MELPHALAN,
CYCLOPHOSPHAMIDE, PREDNISONE (MCP) FOR TREATING PATIENTS WITH
WALDENSTRÖM’S MACROGLOBULINEMIA
M.T. Petrucci, O. Annibali, V. Martini, M.C. Tirindelli, P.
Del Bianco, C. Fossati,
F. Mandelli, G. Avvisati, R. Foà (University “La
Sapienza”, Rome, Italy)
|
EFFECT OF BORTEZOMIB
ON BONE DISEASE IN MULTIPLE MYELOMA
E. Terpos, M. Politou, L. Armstrong, C. Henderson, E. Kanfer,
J.F. Apperley,
A. Rahemtulla (Faculty of Medicine Imperial College, London,
United Kingdom) |
|
A PHASE I/II
MULTICENTER, SAFETY AND EFFICACY STUDY OF COMBINATION TREATMENT
WITH MELPHALAN, ARSENIC AND VITAMIN C (ASCORBIC ACID) (MAC)
IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
J.R. Berenson (Institute for Myeloma & Bone Cancer Res,
Los Angeles, USA) |
FACTORS PREDICTIRE OF CLINICAL
OUTCOME WITH BORTEZOMIB
(VELCADE®) IN PATIENTS WITH RELAPSED, REFRACTORY MULTIPLE
MYELOMA
P.G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath,
D. Irwin, S.V. Rajhumar, T. Hideshima, H. Xiao, D.L. Esseltine,
D. Schenkein, K. Anderson (Dana Farber Cancer Institute, Boston,
USA) |
PAD COMBINATION THERAPY (PS-341/BORTEZOMIB,
ADRIAMYCIN AND DEXAMETHASONE) FOR PREVIOUSLY UNTREATED PATIENTS
WITH MULTIPLE MYELOMA
J.D. Cavenagh, N. Curry, J. Stec, C. Morris, M. Drake, S. Agrawal,
P. Smith, D. Schenkein, D. Esseltine, H. Oakervee (St. Bartholomew’s
Hospital, London, United Kingdom) |
THE SAFETY OF PROLONGED THERAPY
WITH THE PROTEASOME INHIBITOR BORTEZOMIB (VELCADE®) IN RELAPSED
AND/OR REFRACTORY MULTIPLE MYELOMA (MM)
J.R. Berenson, S. Jagannath, B. Barlogie, D. Siegel, R. Alexanian,
D. Irwin, G. Srkalovic, P.G. Richardson, D.L. Esseltine, K.C.
Anderson Institute for Myeloma and Bone Cancer Re, Los Angeles,
USA) |
CHARACTERIZATION AND REVERSIBILITY
OF PERIPHERAL
NEUROPATHY IN PATIENTS WITH ADVANCED MULTIPLE MYELOMA TREATED
WITH BORTEZOMIB (VELCADE®). THE SUMMIT AND CREST STUDY GROUP.
P. Richardson, H. Briemberg, S. Jagannath, B. Barlogie, J.R.
Berenson, S. Singhal, D.T. Siegel, D.H. Irwin, M.W. Schuster,
G. Srkalovic, R. Orlowski, D. Esseltine, P. Wen, A. Amato, K.C.
Anderson (Dana-Farber Cancer Inst, Boston, USA) |
BORTEZOMIB IN COMBINATION
WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED
AND/OR REFRACTORY MULTIPLE MYELOMA
S. Jagannath, P.G. Richardson, B. Barlogie, J.R. Berenson, S.
Singhal, D. Irwin, G. Srkalovic, D. Schenkein, D. Esseltine,
K.C. Anderson (Salick Health Care Research Netwk, New York,
USA) |
BORTEZOMIB AND MELPHALAN
COMBINATION THERAPY
IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM): A PHASE I/II
STUDY
J.R. Berenson, H.H. Yang, R. Swift, K. Sadler, R. Vescio, J.
Adams, D. Schenkein (Institute for Myeloma & Bone Cancer
Res, Los Angeles, USA) |
|
|
EVALUATION OF
THE SEVERITY AND RISK OF THROMBOCYTOPENIA WITH BORTEZOMIB THERAPY
IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA
S. Lonial, E.K. Waller, P.G. Richardson, S. Jagannath, D. Francis,
M. Lehman, C. Torre, B. Barlogie, J.R. Berenson, S. Singhal,
D.P. Schenkein, D.L. Esseltine, J. Anderson, H. Xiao, L.T. Heffner,
K.C. Anderson (Winship Cancer Institute, Emory Univ., Atlanta,
USA) |
PHASE I STUDY OF THE PROTEASOME
INHIBITOR BORTEZOMIB AND PEGYLATED LIPOSOMAL DOXORUBICIN IN
PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES
R.Z. Orlowski, P.M. Voorhees, R.A. Garcia, M.D. Hall, J. Adams,
D.L. Esseltine, D.A. Gabriel, T.C. Shea, H.W. van Deventer,
B.S. Mitchell, E.C. Dees (Univ North Carolina Chapel Hill, Chapel
Hill, USA) |
SURVIVAL AND
PROGNOSTIC FACTORS OF ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN
AT THE NATIONAL CANCER INSTITUTE, EGYPT
I. Sidhom, H. Hussien, Sh. Aboul Naga, M. Zamzam, E. Ebeid,
A. Khairy, A. Kamel, N. El-Sharkawy (National Cancer Institute,
Cairo, Egypt) |
ROLE OF LIPOSOMAL
DAUNORUBICIN, FLUDARABINE AND CYTARABINE (FLAD) IN THE SALVAGE
THERAPY OF ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA
M. Clavio, I. Pierri, A. Garrone, C. Venturino, L. Canepa, M.
Miglino, R. Varaldo, F. Ballerini, G.L. Michelis, M. Balocco,
N. Abdal, S. Gatto, E. Balleari, M. Gobbi Hematology Division,
Genoa University, Genova,
Italy) |
DETECTION OF
MINIMAL RESIDUAL DISEASE IN ACUTE LYMPHOBLASTIC LEUKEMIA USING
AN ALLELE SPECIFIC OLIGONUCLEOTIDE PCR ASSAY
H. Ghaffari, S.H. Dalirifar, K. Alimoghadam, A. Ghavamzadeh
(Tehran University Medical Science, Tehran, Iran) |
SUBTYPE-ORIENTED
STRATEGIES IMPROVE OUTCOME OF OLDER ADULTS (>55 YEARS) WITH
ACUTE LYMPHOBLASTIC LEUKAEMIA: ANALYSIS OF NORTHERN ITALY LEUKAEMIA
GROUP (NILG) DATA
R. Bassan, E.M. Pogliani, G. Rossi, E. Di Bona, P. Polistena,
P. Fabris, G. Lambertenghi-Deliliers, E. Angelucci, C. Minotto,
T. Intermesoli, E. Oldani, T. Barbui (Ospedali Riuniti Bergamo,
Bergamo, Italy) |
SUBTYPE-ORIENTED
STRATEGIES IMPROVE SURVIVAL IN ADULT T-ALL: ANALYSIS OF NORTHERN
ITALY LEUKEMIA GROUP (NILG) STUDIES SINCE 1991
R. Bassan, E. Di Bona, E.M. Pogliani, G. Rossi, A. Cortelezzi,
E. Angelucci, P. Polistena, P. Fabris, D. Mattei, F. Ciceri,
S. Morandi, T. Intermesoli, E. Oldani, T. Barbui (Ospedali Riuniti
Bergamo, Bergamo, Italy) |
|
POLYMORPHISM
OF THE THIOPURINE S-METHYLTRANSFERASE GENE AND THE INDIVIDUALIZED
TREATMENT FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
D-C. Liang, L-Y. Shih, C-F. Huang, I-J. Hung, C-P. Yang, S-H.
Chen, T-H. Jaing, H-C. Liu (Mackay Memorial Hospital, Taipei,
Taiwan) |
RETROSPECTIVE COMPARISON
OF QUALITATIVE AND QUANTITATIVE RT-PCR IN DIAGNOSING AND MONITORING
THE ALL1-AF4 FUSION TRANSCRIPT IN PATIENTS WITH ACUTE LYMPHOBLASTIC
LEUKAEMIA
C. Cimino, L. Elia, E. Gottardi, G. Floriddia, R. Grillo, F.
Ciambelli, M. Luciani, P. Chiusolo, R. Invernizzi, G. Meloni,
R. Foà (University “La Sapienza”, Rome, Italy) |
HETEROGENEITY OF CHILDHOOD
PH+ALL AS ASSESSED BY MRD MONITORING WITH COMPARATIVE QUALITATIVE
AND REAL TIME RT-PCR
G. Cazzaniga, V. Rossi, G. Fazio, M. Spinelli, G. Masera, G.
Basso, A. Biondi (Centro Ricerca Tettamanti, Monza, Italy) |
VINCRISTINE, DEXAMETHASONE
AND DAUNOXOME (VDXD) THERAPY IN ELDERLY ALL PATIENTS: AN UPDATE
M. Offidani, L. Corvatta, L. Malerba, M. Marconi, R. Centurioni,
F. Leoni, M. Catarini, A.R. Scortechini, M.C. Masia, P. Leoni
(Azienda Ospedali Riuniti Ancona, Ancona, Italy) |
RESULTS OF PETHEMA ALL-96
PROTOCOL FOR STANDARD RISK ADULT ALL PATIENTS
J.M. Ribera, A. Oriol, M.A. Sanz, E. Abella, M. Tormo, E. Del
Potro, J. Bueno, C. Grande, J. Fernández-Calvo, M. Orts,
A. Novo, C. Rivas, J.M. Hernández-Rivas, E. Feliu, J.J.
Ortega (ICO - Hosp Univ Germans Trias i Pujol, Badalona, Spain) |
ADULT T-CELL ACUTE LYMPHOBLASTIC
LEUKEMIA: CLINICAL CHARACTERISTICS AND RESULTS OF TREATMENT
ACCORDING TO THE IMMUNOLOGIC PHENOTYPE IN PATIENTS TREATED WITH
TWO TRIALS OF THE SPANISH PETHEMA GROUP
B. Xicoy, A. Oriol, J.M. Ribera, M. Sanz, E. Abella, M. Tormo,
E. Del Potro, J. Bueno, C. Grande, J. Fernandez-Calvo, M. Orts,
A. Novo, C. Rivas, J.M. Hernandez-Rivas, J.J. Ortega (Institut
Català d’Oncologia, HUGTiP, Badalona, Spain) |
PROTEASOME INHIBITORS - A
POTENCIAL THERAPEUTIC APPROACH IN ACUTE LYMPHOBLASTIC LEUKEMIA
A.B. Sarmento Ribeiro, M.A.R.F. Dourado, C. Costa, P.R. Machado,
I. Araújo, S. Vale Pereira, T. Silva, A. Paiva, A.M.
Pinto, F. Regateiro, C.R. Oliveira (University Hospital of Coimbra,
Coimbra, Portugal) |
IMATINIB IN ADULT AND ELDERLY
PH+ ALL PATIENTS: PRELIMINARY RESULTS OF THE GIMEMA PROSPECTIVE
STUDY LAL0201
M. Vignetti, P. Fazi, G. Meloni, A. Chiarenza, M. Malagola,
F. Fabbiano, A. Recchia, M.G. Kropp, M. Offidani, S. Palmieri,
D. Cilloni, G. Torelli, L. Elia, M. Ribersani, M. Baccarani,
F. Mandelli (University La Sapienza, Roma, Italy) |
|
|
PREDNISONE PRE-TREATMENT
IS A PROGNOSTIC FACTOR FOR COMPLETE REMISSION IN ADULT ACUTE
LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS
M. Vignetti, G. Meloni, F. Di Raimondo, G. Mele, G. Fioritoni,
G. Specchia, M. Luppi, A. Tedeschi, F. Fabbiano, S. Sica, N.
Cascavilla, A. Camera, G. Todeschini, A. Vitale, R. Foà,
F. Mandelli (University “La Sapienza”, Rome, Italy) |
POTENTIAL USE OF CD40L+ BCP-ALL
CELLS-LOADED DC TO RIGGER ANTITUMOR IMMUNITY IN B CELL PRECURSOR
ACUTE LYMPHOBLASTIC LEUKEMIA.
G. D’Amico, M. Bonamino, V. Marin, A. Biondi (Centro Ricerca
M. Tettamanti, Monza, Italy) |
RECOGNITION OF
MIC-A AND ULBP3 BY VD1 T CELLS IN B-CLL: IMPLICATIONS FOR ANTI-CANCER
SURVEILLANCE
M.R. Zocchi, A. Poggi, S. Catellani, M. Gobbi, A. Steinle, P.
Ghia, S. Stella, F. Caligaris-Cappio (IRCCS San Raffaele, Milan,
Italy) |
PRAME ANTIGEN
IS FREQUENTLY EXPRESSED IN LYMPHOPROLIFERATIVE DISEASES
R. Proto-Siqueira, E.M. Rego, V. Filonenko, A.J. Simpson, A.B.
Garcia, E.G. Rizzatti, R.P. Falcao, M.A. Zago (Faculty of Medicine
of Ribeirao Preto, Ribeirao Preto, Brazil) |
P53 EXPRESSION
IN CHRONIC LYMPHOCYTIC LEUKEMIA
I.M. Zemtsova, T.P. Zagoskina, V.I. Shardakov (Kirov Research
Institute of Hematology, Kirov, Russian Federation) |
TRANSFERRIN RECEPTOR-1
AND -2 EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA
A. Smilevska, K. Stamatopoulos, M. Samara, I. Chiotoglou, A.
Tsompanakou, N. Stavroyianni, I. Athanasiadou, A. Hadzidimitriou,
A. Athanasiadou, G. Paterakis, N. Vamvakopoulos, R. Saloum,
A. Fassas, P. Kollia, A. Anagnostopoulos (G. Papanicolaou Hospital,
Thessaloniki, Greece) |
IMMUNOGLOBULIN
KAPPA GENE LOCUS REARRANGEMENTS TO THE KAPPA DELETING ELEMENT
IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH CLONOTYPIC LAMBDA LIGHT
CHAIN
A. Hadzidimitriou, C. Belessi, K. Stamatopoulos, N. Stavroyianni,
T. Smilevska, A. Tsompanakou, E. Kalagiakou, G. Paterakis, V.
Douka, V. Tachynopoulou, K. Valianatou, R. Saloum, A. Anagnostopoulos,
A. Fassas, N. Laoutaris (G. Papanicolaou Hospital, Thessaloniki,
Greece) |
DEREGULATION
OF NOTCH2 SIGNALING IN B-CLL
H. Hubmann, J.D. Schwarzmeier, M. Duechler, M. Hilgarth, D.
Mitteregger, M. Shehata (University of Vienna, Medical school,
Vienna, Austria) |
PROTEASOME INHIBITOR
INDUCED APOPTOSIS IN B-CLL
CELLS IS ASSOCIATED WITH NOTCH2 INACTIVATION AND DOWNREGULATION
OF CD23 M.D. Duechler, J.D. Schwarzmeier, M. Shehata,
M. Hilgarth, R. Hubmann (AKH Vienna, Vienna, Austria) |
|
INVOLVEMENT OF
NUCLEOSIDE TRANSPORTERS IN NUCLEOSIDEDERIVED DRUG RESPONSIVENESS
IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
S. Marce, M. Molina, I. Huber, B. Bellosillo, N. Villamor, F.J.
Casado, E. Montserrat, M. Pastor-Anglada, D. Colomer (Hospital
Clinic, Barcelona, Spain) |
RAPAMYCIN INHIBITS MITOGEN-ACTIVATION
OF B-CLL CELLS
M. Shehata, J.D. Schwarzmeier, M. Hilgarth, D. Mitteregger,
D. Heintel, A. Gaiger, R. Hubmann, M. Duechler, U. Jaeger (Vienna
University, Vienna, Austria) |
FISH REVEALS MULTIPLE CELLULAR
CLONES MARKED BY DIFFERENT NUMBERS OF D13S319 AND RB1 ALLELES
IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL)
P.B. Bernasconi, E. Orlandi, P.M. Cavigliano, I. Giardini, M.
Boni, S. Calatroni, B. Rocca, J. Quarna, R. Zappatore, M. Caresana,
M. Lazzarino (Policlinico San Matteo IRCCS, Pavia, Italy) |
INDUCTION OF APOPTOSIS IN
B-CLL CELLS BY BY PI3-K INHIBITORS AND SIRNA
M. Shehata, J.D. Schwarzmeier, M. Hilgarth, D. Mitteregger,
A. Hoelbl, C. Lehner, D. Heintel, A. Gaiger, R. Hubmann, M.
Duechler, U. Jaeger (Vienna University, Vienna, Austria) |
EXPRESSION AND FUNCTION OF
THE CXCR5 CHEMOKINE RECEPTOR ON B LYMPHOCYTES FROM PATIENTS
WITH B CELL CHRONIC LYMPHOCYTIC LEUKEMIA AND OTHER B CELL NEOPLASIAS.
J.A. Burger, A. Bürkle, A. Schmitt-Gräff, D. Behringer,
M. Krome (Division of Hematology/Oncology, Freiburg, Germany) |
GENE EXPRESSION PROFILING
IN CHRONIC LYMPHOCYTIC LEUKEMIA: CORRELATION WITH DISEASE STABILITY
AND PROGRESSION, AND P53 MUTATIONS
S. Chiaretti, B. Ding, R. Gentleman, A. Guarini, F.R. Mauro,
E. Ghia, G. Gaidano, J. Ritz, R. Foà (Dana Farber Cancer
Institute, Boston, USA) |
THE BONE MARROW HISTOLOGICAL
SIGNATURE OF T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKAEMIA
N. Osuji, A. Wotherspoon, E. Matutes, D. Catovsky (Royal Marsden/Institute
Cancer Research, London, United Kingdom) |
CD43 ANTIGEN EXPRESSION IN
B-CELL CHRONIC LYMPHOPROLIFERATIVE DISEASES
C. Benet Campos, R. Andreu Lapiedra, R. García Delgado,
P. Leon Moreno, M. Calabuig Muñoz, M. Fernandez Zarzoso,
P. Ribas García, S. Ferrer Bordes, M.J. Sayas Llopis,
J. Rafecas Renau (Hospital Dr. Peset, Valencia, Spain) |
BONE MARROW ASPIRATE VERSUS
BONE MARROW BIOPSY IN DETECTING NON HEMATOLOGICAL MALIGNANCIES
G. Zini, M. Garzia, A. Di Mario, E. Rossi, L.M. La Rocca, G.
D’Onofrio (Catholic University of Sacred Heart, Rome,
Italy) |
|
|
SPLEEN HISTOLOGY
IN LEUKAEMIAS OF LARGE GRANULAR LYMPHOCYTES
N. Osuji, A. Wotherspoon, E. Matutes, D. Catovsky (Royal Marsden/Institute
Cancer Research, London, United Kingdom) |
THE INFLUENCE
OF SHORT CULTURE OF LEUKEMIC BLASTS ON THE EXPRESSION OF CO-STIMULATORY
MOLECULES AND THE ABILITY TO INDUCE THE PROLIFERATION OF AUTOLOGOUS
T-LYMPHOCYTES.
K. Kapelko-Slowik, D. Urbaniak-Kujda, D. Wolowiec, B. Tomaszewska-
Toporska, B. Jazwiec, I. Frydecka, K. Kapelko-Slowik, K. Kuliczkowski
(Wroclaw Medical University, Wroclaw, Poland) |
UROKINASE PLASMINOGEN
ACTIVATOR RECEPTOR AND SOLUBLE MATRIX METALLOPROTEINASE-9 IN
ACUTE MYELOID LEUKEMIA PATIENTS: A POSSIBLE RELATION TO DISEASE
INVASION
S. Aref, M. El-Sherbiny, M. Mabed, A. Menessy, M. El-Refaei
(Mansoura Faculty of Medicine, Mansoura, Egypt) |
ELEVATED SKP2
PROTEIN EXPRESSION IN ACUTE MYELOGENOUS LEUKEMIA: ITS ASSOCIATION
WITH THE CONSTITUTIVE PHOSPHORYLATION OF PTEN PROTEIN AND POOR
PROGNOSIS
Y.H. Min, J.W. Cheong, M.H. Lee, J.Y. Kim, S.T. Lee, J.S. Hahn,
Y.W. Ko (Yonsei University College of Medicine, Seoul, South-Korea) |
CYTOPLASMIC MISLOCALIZATION
OF P27KIP1 PROTEIN IS ASSOCIATED WITH CONSTITUTIVE PHOSPHORYLATION
OF AKT/PKB AND POOR PROGNOSIS IN ACUTE MYELOGENOUS LEUKEMIA
Y.H. Min, J.W. Cheong, M.H. Lee, J.Y. Kim, S.T. Lee, J.S. Hahn,
Y.W. Ko (Yonsei University College of Medicine, Seoul, South-Korea) |
EVOLUTIONARY
ALGORITHMS IN LEUKEMOGENESIS. A HYPOTHETICAL MODEL
A. Cucuianu (“Ion Chiricuta” Cancer Institute, Cluj-Napoca,
Romania) |
XIAP AND XAF-1
ARE STRONG PROGNOSTIC MARKERS IN AML
K. Tobal, D. Livesey, A. Awan, J.A. Liu Yin, K. Tobal (Manchester
Royal Infirmary, Manchester, United Kingdom) |
FLT3 GENE MUTATIONS
IN ACUTE MYELOID LEUKAEMIA: ASSOCIATION WITH NORMAL AND T(15;17)
KARYOTYPES
G.F. How, L.T. Tan, L.C. Lim (Singapore General Hospital, Outram
Road, Singapore) |
USING INTERFERON
CAPTURE TO IDENTIFY ANTI-RECIPIENT AML ACTIVITY IN IN-VITRO
PRIMED, MATCHED DONOR LYMPHOCYTES
P. Baines, J. Fisher, T.G. Hoy, K. Wilson, A.K. Burnett (University
Hospital of Wales, Cardiff, United Kingdom) |
|
CHARACTERIZATION
OF BONE MARROW STROMAL CELLS FROM ACUTE MYELOID LEUKEMIA PATIENTS
A. Poggi, A-M. Massaro, S.M. Negrini, I. Pierri, M. Gobbi, M.R.
Zocchi (National Institute for Cancer Research, Genoa, Italy) |
ACUTE MYELOID LEUKEMIA WITH
MULTILINEAGE DYSPLASIA PRESENTING AS DE NOVO DISEASE: DIVERSE
PROGNOSIS ACCORDING TO CYTOGENETICS
J. Esteve, M. Rozman, M. Camós, J-L. Aguilar, C. Uriburu,
D. Costa, A. Carrió, N. Villamor, M. Aymerich, E. Campo,
E. Montserrat (Hospital Clínic, Barcelona, Spain) |
AMPLIFICATION OF THE 11Q23
REGION ON DOUBLE MINUTES AND HOMOGENEOUSLY STAINING REGION ON
TWO UNRELATED CLONES IN A PATIENT WITH ACUTE MYELOID LEUKAEMIA
M2
I. Vazquez, I. Lahortiga, X. Agirre, J.L. Vizmanos, M. Valgañon,
M.J. Larrayoz, M.T. Ardanaz, N.J. Zeleznik-Le, M.J. Calasanz,
M.D. Odero (University of Navarra, Pamplona, Spain) |
HIGH EXPRESSION OF APAF-1LN
IN ACUTE MYELOID LEUKEMIA MAY BE ASSOCIATED WITH FAILURE OF
REMISSION INDUCTION THERAPY
B.D. Benites, T.S.I. Salles, A. Fattori, C. Hackel, I.H. Lorand-Metze,
C.A. Souza, S.T.O. Saad (University of Campinas, Campinas, Brazil) |
ANALYSIS OF THE PROTO-ONCOGENES
A -, B - AND C-RAF IN ACUTE MYELOID LEUKEMIA
A. Zebisch, P.B. Staber, K. Fischereder, C. Bodner, K. Hiden,
W. Linkesch, H.W. Auner, W. Emberger, P. Sovinz, M.G. Schimek,
G. Höfler, H. Sill (Division of Hematology, Graz, Austria) |
RAPID INDUCTION OF APOPTOSIS
VIA A NOVEL DUAL PATHWAY BY 1’-ACETOXYCHAVICOL ACETATE
IN HUMAN LEUKEMIC CELLS
K. Ito, T. Nakazato, A. Murakami, K. Yamato, Y. Miyakawa, N.
Hozumi, H. Ohigashi, Y. Ikeda, M. Kizaki (Keio University School
of Medicine, Tokyo, Japan) |
MUTATION PATTERNS IN CEBPA
GENE IN ADULT PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA AT
DIAGNOSIS AND RELAPSE
L-Y. Shih, C-F. Huang, P-N. Wang, J-H. Wu, T-L. Lin, P. Dunn,
M-C. Kuo, C-C. Tang (Chang Gung Memorial Hospital, Taipei, Taiwan) |
RELATIVE QUANTIFICATION OF
TELOMERASE REVERSE TRANSCRIPTASE (HTERT) BY REAL-TIME POLYMERASE
CHAIN REACTION (PCR) IN TWENTY-THREE ACUTE PROMYELOCYTIC LEUKEMIA
PATIENTS
P.B. Bernasconi, S. Calatroni, C. Klersy, B. Rocca, M. Boni,
P. Cavigliano, I. Giardini, J. Quarna, R. Zappatore, M. Caresana,
M. Lazzarino (Policlinico San Matteo IRCCS, Pavia, Italy) |
|
|
DOWN-REGULATION
OF THE PUTATIVE TUMOR SUPPRESSOR GENE GRAVIN IN ACUTE MYELOID
LEUKEMIA, CHRONIC MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
A. Pellagatti, F. Watkins, L.J. Campbell, N.C.P. Cross, H. Eagleton,
T.J. Littlewood, C. Fidler, J.S. Wainscoat, J. Boultwood (LRF
Molecular Hematology Unit, Oxford, United Kingdom) |
ACUTE MYELOID
LEUKEMIA OF ELDERLY (>60 YEARS) IS AN HETEROGENEOUS DISEASE:
COAGULOPHATHY AND FLT3 MUTATIONS ARE INDEPENDENT PROGNOSTIC
FACTORS FOR SURVIVAL
M. Breccia, R. Latagliata, C. Minotti, G. De Angelis, A. Guarini,
M.S. De Propriis, D. Diverio, I. Carmosino, R. De Cuia, M. Nanni,
G. Alimena, G. Cimino (Ematologia-università “La
Sapienza”, Rome, Italy) |
CEBPA MUTATIONS,
FLT3 ITD AND BAALC EXPRESSION DEFINE DISTINCT PROGNOSTIC SUBSETS
IN NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA (AML)
E. Oppliger Leibundgut, M. Bienz, M. Ludwig, B.U. Mueller, M.F.
Fey, T. Pabst (Div. of Hematology, University Hospital, Bern,
Switzerland) |
COMPLETE MUTATIONAL
ANALYSIS OF THE COMMONLY DELETED REGION UNDERLYING DEL(9Q) ACUTE
MYELOID LEUKAEMIA
A.J. Peniket, S. Daly, Z. Zhao, J. Boultwood, J. Wainscoat,
D. Sweetser (John Radcliffe Hospital, Oxford, United Kingdom)
|
ELDERLY PATIENS
WITH DE NOVO ACUTE MYELOID LEUKEMIA (AML): PROGNOSTIC FACTORS
IN 113 CASES
E. Luño, C. Sanzo, J.M. Vicente, A. Ramirez, D. Carrera,
A. Martinez (Hospital Central de Asturias, Oviedo, Spain) |
PROGNOSTIC FACTORS
IN PATIENTS DIAGNOSED DE NOVO ACUTE MYELOID LEUKEMIA (AML) WITH
<65 YEARS OLD
E. Luño, C. Sanzo, J.M. Vicente, F. Jonte, A. Ramirez,
S. Gil, A. Martinez (Hospital Central de Asturias, Oviedo, Spain) |
FREQUENT ABERRANT
BRCA1 METHYLATION IN ACUTE MYELOID LEUKEMIA (AML) SECONDARY
TO BREAST CANCER TREATMENT
A. Scardocci, L. Valentini, M. Zollino, G. Leone, M.T. Voso
(Inst. of Hematology, Rome, Italy) |
DIFFERENCES IN
ANTI-APOPTOTIC AND MULTIDRUG RESISTANCE PHENOTYPES IN ELDERLY
VS YOUNGER ACUTE MYELOID LEUKEMIA PATIENTS ARE RELATED TO THE
MATURATION CHARACTERISTIC OF BLAST CELLS
M.B. Vidriales, L. Suarez, M.J. Moreno, A. López, J.
García-Laraña, C. Pérez-López, M.
Tormo, E. Lavilla, C. López-Berges, M. de Santiago, J.F.
San Miguel, A. Orfao, PETHEMA Cooperative Group (University
Hospital, Salamanca, Spain) |
POLYMORPHISMS
OF CYP1A1 AND GLUTHATIONE S-TRANSFERASE AND SUSCEPTIBILITY TO
ADULT ACUTE MYELOID LEUKEMIA.
F. D’Alò, A. Scardocci, G. Massini, F. Guidi, S.
Hohaus, G. Leone, M.T. Voso (Università Cattolica del
Sacro Cuore, Roma, Italy) |
|
DEVELOPMENT OF
THE EFFECTIVE TUMOR ANTIGEN SENSITIZATION METHODS FOR DENDRITIC
CELLS DERIVED FROM PATIENTS WITH MYELOGENOUS LEUKEMIA
K.W. Kim, S.Y. Park, S.Y. Shin, E.H. Lee (Deajeon St. Mary’s
Hospital, Daejeon, South-Korea) |
TUMOR NECROSIS FACTOR (TNF)
PATHWAY IS DOWN-REGULATED IN APL: A GENE EXPRESSION PROFILING
STUDY
M.Z. Garcia-Casado, J. Cervera, J.C. Pajuelo, A. Valencia, C.
Garcia, G. Martin, P. Bolufer, E. Barragan, A. Rodriguez, N.
Martinez, S. Cantero,M.J. Remigia, M.L. Marty, M.A. Piris, M.A.
Sanz (University Hospital “La Fe”, Valencia, Spain) |
PERICYTE COVERAGE
OF ABNORMAL VESSELS IN THE MYELOFIBROSIS BONE MARROW
M.K. Zetterberg, J. Palmblad (Huddinge University hospital,
Stockholm, Sweden) |
ANALYSIS OF XCIP AND TELOMERASE
ACTIVITY IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA
R. Mangerini, N. Pujic, D. Rapezzi, A. Gallamini, S. Casciaro,
D. Mattei, G.F. Gaetani, A.M. Ferraris (Istituto Nazionale Ricerca
sul Cancro, Genova, Italy) |
COMPARISON BETWEEN ANAGRELIDE
AND HYDROXYUREA IN THEIR ACTIVITIES AGAINST HAEMATOPOIETIC CELL
GROWTH AND DIFFERENTIATION
J.D. Erusalimsky, G. Wang, C. Skene, Y. Hong (University College
London, London, United Kingdom) |
ACUTE LEUKAEMIA/MYELODYSPLASTIC
SYNDROME [AL/MDS] TRANSFORMATION RATES IN ANAGRELIDE TREATED
PATIENTS WITH ESSENTIAL THROMBOCYTHAEMIA [ET] AND POLYCYTHAEMIA
VERA [PV]
G.I. Fiddler, A. Lyne, M. Boogaerts (Shire Pharmaceutical Development
Ltd, Basingstoke, United Kingdom) |
NEUTROPHIL PRV-1 GENE EXPRESSION
IN MYELOPROLIFERATIVE, MYELODYSPLASTIC AND REACTIVE BLOOD DISORDERS
J. Zhang, A. Pellagatti, L. Campbell, H. Eagleton, S. Gal, C.
Fidler, J. Boultwood, J.S. Wainscoat (University of Oxford,
Oxford, United Kingdom) |
CIRCULATING ENDOTHELIAL PROGENITOR
CELLS ARE INCREASED IN PATIENTS WITH MYELOFIBROSIS WITH MYELOID
METAPLASIA
V. Rosti, M. Massa, I. Ramajoli, R. Campanelli, A. Pecci, G.
Viarengo, M Marchetti, G. Barosi (Policlinico San Matteo, Pavia,
Italy) |
POLYCYTHEMIA AND HIGH SERUM
ERYTHROPOIETIN IN YOUNG PATIENTS: OCCURRENCE OF VHL MUTATION
M.L. Randi, A. Murgia, M.C. Putti, A. Casarin (Padua University,
Padua, Italy) |
|
|
UTILITY OF HUMARA
PCR ASSAY IN A COHORT OF SPANISH PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
AND POLYCYTHEMIA VERA.
L. Zamora, B. Espinet, L. Florensa, C. Besses, B. Bellosillo,
E. Abella, E. Puigdecanet, M. Musset, S. Woessner, S. Serrano,
F. Sole (Hospital del Mar, Barcelona, Spain) |
LEUKOCYTE AND
PLATELET ACTIVATION IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
(ET) AND POLYCYTHEMIA VERA (PV)
A. Falanga, M. Marchetti, A. Vignoli, D. Balducci, T. Barbui
(Ospedali Riuniti Bergamo, Bergamo, Italy) |
A NEW PROGNOSTIC
MODEL (MPI) FOR PATIENTS WITH MYELOFIBROSIS
K. Strasser-Weippl, M. Steurer, M. Kees, F. Augustin, A. Tzankov,
S. Dirnhofer, N. Zojer, H. Gisslinger, H. Ludwig (Wilhelminen
Hospital, Vienna, Austria) |
CYTOGENETIC ABNORMALITIES
IN MYELOFIBROSIS DETERMINED BY FISH
K. Strasser-Weippl, M. Steurer, M. Kees, F. Augustin, A. Tzankov,
S. Dirnhofer, H. Gisslinger, N. Zojer, H. Ludwig (Wilhelminen
Hospital, Vienna, Austria) |
SECOND MALIGNANCIES
IN ET: A RETROSPECTIVE ANALYSIS OF 306 PATIENTS WITH PROLONGED
OBSERVATION TIME FROM A SINGLE INSTITUTION
F. Rossi, P. Usardi, F. Onida, P. Faccini, R. Calori, M. Colombi,
A.T. Maiolo, G. Lambertenghi-Deliliers, F. Radaelli (IRCCS Ospedale
Maggiore of Milan, Milan, Italy) |
DIFFERENCES IN
GENDER AND CLINICAL-HEMATOLOGICAL FINDINGS BETWEEN THE 4Q-/CHRONIC
EOSINOPHILIC LEUKEMIA AND IDIOPATHIC HYPEREOSINOPHILIC SYNDROMES
R. La Starza, R. La Starza, P. Marynen, A. Aventin, G. Specchia,
A. Cuneo, L. Luciano, R. Foà, C. Nozzoli, M. Cazzola,
R. Invernizzi, C. Sambani, M.F. Martelli, C. Mecucci (Policlinico
Monteluce, Perugia, Italy) |
CD8+ T CELL DOSE
AFFECTS DEVELOPMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE FOLLOWING
ALLOGENEIC TRANSPLANTATION WITH ANTITHYMOCYTE GLOBULIN-BASED
REDUCED-INTENSITY CONDITIONING REGIMEN
M. Mohty, S. Bagattini, C. Chabannon, C. Faucher, V.J. Bardou,
K. Bilger, N. Vey, A.M. Stoppa, D. Coso, B. Gaugler, P. Ladaique,
D. Maraninchi, D. Olive, P. Viens, D. Blaise (Institut-Paoli-Calmettes,
Marseille, France) |
|
GRAFT-VERSUS-MYELOMA
EFFECT FOLLOWING REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM
CELL TRANSPLANTATION
M. Mohty, J.M. Boiron, G. Damaj, A.S. Michallet, J.O. Bay, R.
Tabrizi, C. Faucher, J.A. Gastaut, N. Vey, A.M. Stoppa, D. Maraninchi,
M. Michallet, D. Blaise (Institut-Paoli-Calmettes, Marseille,
France) |
CLINICAL FOLLOW-UP INDICATES
DIFFERENTIAL OUTCOME OF EXTRAMEDULLARY VERSUS MEDULLARY RELAPSE
AFTER AUTOLOGOUS OR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
IN MULTIPLE MYELOMA
R. Zeiser, B. Deschler, H. Bertz, J. Finke, M. Engelhardt (Freiburg
University Medical Center, Freiburg, Germany) |
REDUCED INTENSITY TRANSPLANTATION
FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME
A. Busca, F. Locatelli, G. Rossi, C. Ceretto, F. Marmont, E.
Gallo, M. Falda (Molinette, Turin, Italy) |
INDUCTION OF AGVHD AFTER
ALLOGENEIC HEMATOPOETIC STEM CELL TRANSPLANTATION FOR REFRACTORY
OR RELAPSED ACUTE LEUKEMIA
J. Sun, F.Y. Meng, Q. Liu, D. Xu, B. Xu, X.L. Liu, R.Q. Wei
(Nanfang Hospital, 1st Milit Med Uni, Guangzhou, China) |
RECOVERY OF SPERMATOGENESIS
IN LONG-TERM SURVIVORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
A. Rovó, S. Meyer-Monard, D. Heim, J.R. Passweg, W. Holzgreve,
A. Gratwohl, A. Tichelli, C. De Geyter (University Hospitals
Basel, Basel, Switzerland) |
ALLOGENEIC STEM CELL TRANSPLANTATION
FROM UNRELATED DONORS IN SWITZERLAND. IMPACT OF MOLECULAR HLA
MATCHING
R. Passweg, Y. Chalandon, J. Halter, T. Guengoer, A. Tichelli,
G. Nicoloso de Faveri, B. Chapuis, R. Seger, U. Schanz, A. Gratwohl,
E. Roosnek, J-M. Tiercy (Kantonsspital, Basel, Switzerland) |
RESPIRATORY VIRUSES ARE DETECTED
FREQUENTLY IN ADULT RECIPIENTS OF STEM CELL TRANSPLANTATION
WITH RESPIRATORY TRACT DISEASE
M.G.J. van Kraaij, L.J.R. van Elden, A.M. van Loon, K.A.W. Hendriksen,
L. Laterveer, A.W. Dekker, M. Nijhuis (University Medical Centre
Nijmegen, Nijmegen, The Netherlands) |
ALLOGENEIC HEMATOPOIETIC
STEM-CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME AND SECONDARY
ACUTE MYELOID LEUKEMIA: OUTCOME IS DEPENDENT ON DISEASE BIOLOGY
A. Shimoni, I. Hardan, M. Yeshurun, N. Shem-Tov, A. Avigdor,
I. Ben-Bassat, A. Nagler (Chaim Sheba Medical Center, Tel-Hashomer,
Israel) |
|
|
RECONSTITUTION
OF CYTOMEGALOVIRUS (CMV)-SPECIFIC CD4+ T CELLS FOLLOWING ALLOGENEIC
STEM CELLS TRANSPLANTATION-IMPORTANCE OF CD4 RECOVERY, SOURCE
OF STEM CELL AND HOST FACTORS
B. Pourgheysari, R. Bruton, K. Piper, J. Arrazi, M. Cobbald,
P.A.H. Moss (University of Birmingham, Birmingham, United Kingdom) |
COMMUNITY RESPIRATORY
VIRUS INFECTIONS (CRV) IN ADULT RECIPIENTS OF A HAEMATOPOIETIC
STEM CELL TRANSPLANTATION (SCT) FOR A HEMATOLOGICAL MALIGNANCY:
RESULTS FROM SINGLE-CENTER STUDY
R. Parody Porras, R. Martino, E. Rámila, J. Sierra, N.
Rabella (Hospital Sant Pau, Barcelona, Spain) |
T-LYMPHOCYTE
RECOVERY FOLLOWING NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
IS FASTER THAN AFTER CONVENTIONAL TRANSPLANTATION
M.J. Jimenez, C. Martinez, G. Ercilla, E. Carreras, M. Rovira,
A. Urbano- Ispizua, F. Fernandez-Aviles, C. Talarn, N. Amezaga,
R. Martino, A. Broto, J. Sierra, E. Montserrat (Hospital Clinic,
Barcelona, Spain) |
T-CELL DEPLETION
WITH LOW-DOSE ALEMTUZUMAB IN REDUCED INTENSITY ALLOGENEIC TRANSPLANTS
IS ASSOCIATED WITH LOW INCIDENCE OF GRAFT-VERSUS-HOST DISEASE
(GVHD) AND TRANSPLANT-RELATED-MORTALITY (TRM).
A.D. Dodero, R. Milani, V. Montefusco, F. Zallio, L. Farina,
M. Carrabba, E. Rizzo, P. Corradini (Istituto Nazionale dei
Tumori, Milano, Italy) |
HIGHLY EFFECTIVE
TOPICAL TACROLIMUS TREATMENT IN SEVERE ORAL CHRONIC GRAFT-VERSUS-HOST
DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
M. Stadler, O. Starke, C.W.M. Reuter, A. Eckardt, B. Hertenstein
(Hannover Medical School, Hannover, Germany) |
TREATMENT OF
REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE WITH RAPAMYCIN
M. Stadler, C.W.M. Reuter, C. Elser, A. Franzke, S. Buchholz,
M. Eder, E. Dammann, A. Ganser, B. Hertenstein (Hannover Medical
School, Hannover, Germany) |
REDUCED-INTENSITY
CONDITIONING FOLLOWED BY ALLOGENEIC TRANSPLANTATION: POOR OUTCOME
IN SECONDARY VERSUS DE-NOVO ACUTE MYELOID LEUKEMIAS
P.C. Corradini, A. Dodero, R. Milani, C. Tarella, G. Bandini,
A. Locasciulli, M. Bernardi, M. Lucesole, A. Busca, D. Soligo,
A.M. Gianni, M. Bregni, A. Olivieri (Istituto Nazionale dei
Tumori, Milano, Italy) |
TUMORAL EPSTEIN-BARR
VIRUS (EBV) VIRAL LOAD IN POSTTRANSPLANTATION LYMPHOPROLIFERATIVE
DISORDERS AND HIV-ASSOCIATED LYMPHOMA
R.A. Epaulard, J.P. Brion, J.P. Stahl, J.J. Sotto, M. Peoc’h,
P. Morand, R. Gressin, S. Fafi-Kremer, S. Courby (Centre Hospitalo-Universitaire,
Grenoble, France) |
|
NON-MYELOABLATIVE
SIBLING ALLOGRAFTS IN ADULTS WITH INTERMEDIATE PROGNOSIS ACUTE
MYELOID LEUKAEMIA (AML) IN FIRST COMPLETE REMISSION (CR1)
A.P. Grigg, P. Shuttleworth, P. Bardy, J. Gibson, S. Durrant,
K. Bradstock (Royal Melbourne Hospital, Victoria, Australia) |
COMPARISSON BETWEEN CONVENTIONAL
AND REDUCED INTENSITY CONDITIONING REGIMENS: GVHD AFTER ALLOGENEIC
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
M. Diez-Campelo, J.A. Pérez-Simón, E.M. Ocio,
C. Castilla, M.D. Caballero, M.V. Mateos, F.M. Sanchez-Guijo,
L. Vazquez, M.C. Cañizo, J.F. San Miguel (Hospital Universitario
de Salamanca, Salamanca, Spain) |
TOPIC THERAPY ON GUT ACUTE
GRAFT VERSUS HOST DISEASE (GVHD)
C. Castilla, J.A. Pérez-Simón, F. Sánchez-Guijo,
D. Caballero, M.C. Cañizo, M. Diez-Campelo, E.M. Ocio,
L. Vazquez, J.F. San Miguel (Hospital Clinico de Salamanca,
Salamanca, Spain) |
THE PRION-LIKE
PROTEIN DOPPEL IS EXPRESSED IN BLAST CELLS OF ACUTE LEUKEMIAS
AND MYELODYSPLASTIC SYNDROMES
R. Invernizzi, S. Comincini, E. Travaglino, C. Benatti, I. Del
Vecchio, R. Nano, L. Ferretti (IRCCS Policlinico S. Matteo,
Pavia, Italy) |
HEMATOPOIETIC
MATURATION ABNORMALITIES DETECTED BY FLOW CYTOMETRY ARE USEFUL
FOR DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASIA AND NON-CLONAL
DISORDERS
I. Lorand-Metze, E. Ribeiro (State University of Campinas, Campinas,
Brazil) |
TRISENOX®
(ARSENIC TRIOXIDE) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
(MDS): PRELIMINARY RESULTS OF A PHASE I/II STUDY
N. Vey, F. Dreyfus, A. Guerci, H. Dombret, A. Burnett, A. Bosly,
W. Feremans, D. Bowen, F. Garzon, P. Fenaux (Institut Paoli-Calmettes,
Marseille, France) |
REPRODUCIBILITY
OF FAB AND WHO CLASSIFICATIONS FOR THE DIAGNOSIS OF MYELODYSPLASTIC
SYNDROMES
F. Gomis, M.J. Arilla, A. De Miguel, P. León, F. Ortuño
(Hospital Universitario La Fe, Valencia, Spain) |
BONE MARROW ANGIOGENESIS
AND SERUM LEVELS OF ANGIOGENIN IN PATIENTS WITH MYELODYSPLASTIC
SYNDROMES
F.H. Passam, G. Tsirakis, K. Dambaki, A. Fragou, E.S. Stathopoulos,
D.S. Kyriakou, M.G. Alexandrakis (Sotiria Hospital, Athens,
Greece) |
PROLIFERATING
CELL NUCLEAR ANTIGEN (PCNA) IMMUNOSTAINING IN MYELODYSPLASTIC
SYNDROMES AND ITS PROGNOSTIC SIGNIFICANCE
F.H. Passam, A. Fragou, G. Tsirakis, K. Dambaki, P. Roussou,
E.S. Stathopoulos, D.S. Kyriakou, M.G. Alexandrakis (Sotiria
Hospital, Athens, Greece) |
|
|
EFFICACY AND
SAFETY OF DARBEPOETIN IN MYELODYSPLASTIC SYNDROMES
P. Musto, E. Balleari, A. Falcone, G. Sanpaolo, C. Bodenizza,
A. La Sala, R. Ghio, A.M. Carella (IRCCS “Casa Sollievo
della Sofferenza”, S. Giovanni Rotondo, Italy) |
STUDY OF THE
EFFECT OF CA2 ANTI-TNFA MONOCLONAL ANTIBODY THERAPY ON THE BONE
MARROW (BM) STEM/PROGENITOR CELL RESERVES AND BM STROMAL CELL
FUNCTION IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
A. Boula, A. Damianaki, C. Gemetzi, H. Koutala, M. Psyllaki,
G. Katrinakis, A. Foundoulakis, C. Pontikoglou, A. Kolovou,
F. Markidou, G.D. Eliopoulos, H.A. Papadaki (University of Crete
School of Medicine, Heraklion, Greece) |
ANGIOGENESIS
AND VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION IN THE BONE
MARROW OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES
A. Savic, V. Cemerikic-Martinovic, D. Pejin, N. Popov, S. Popovic
(Clinical Centre Novi Sad, Novi Sad, Serbia) |
CD55 AND CD59
EXPRESSION ON GRANULOCYTES IN MYELODYSPLASTIC SYNDROMS (MDS)
G. Kaiafa, V. Tsavdaridou, A. Papadopoulos, I. Klonizakis, Z.
Giannopoulos, C. Agouridaki, C. Savopoulos, A. Hatzitolios,
V. Papayanis (AHEPA Hospital, Aristotle University, Thessaloniki,
Greece) |
LOW-DOSE DECITABINE
RE-TREATMENT IN OLDER MDS PATIENTS
B. Rüter, J. Pitako, P.W. Wijermans, M. Lübbert (University
of Freiburg Medical Center, Freiburg, Germany) |
ACQUIRED ALPHA
THALASSAEMIA (HAEMOGLOBIN H) IN MYELODYSPLASTIC SYNDROME: HAEMATOLOGICAL
AND MOLECULAR ANALYSES
D.P. Steensma, R.J. Gibbons, D.R. Higgs (University of Oxford,
Headington Oxford, United Kingdom) |
MOLECULAR PATHWAYS
OF RHUEPO RESPONSE IN MDS PATIENTS
N.S. Fracchiolla, C. Pellegrini, I. Silvestris, M. Cortiana,
S. Bosari, A. Cortellezzi, A.T. Maiolo, M.C. Pasquini (Ospedale
Maggiore Policlinico di Milano, Milano, Italy) |
DISEASE-SPECIFIC
PROGNOSTIC FACTORS FOR OUTCOME OF PATIENTS WITH POOR-RISK MYELODYSPLASTIC
SYNDROME (MDS) AND ACUTE MYELOID LEUKEMIA (AML) TREATED WITH
INTENSIVE ANTILEUKEMIC THERAPY
M. Oosterveld, S. Suciu, P. Muus, M. Delforge, A. Belhabri,
C. Aul, D. Selleslag, A. Ferrant, S. Amadori, U. Jehn, F. Mandelli,
U. Hess, B. Labar, F. Beeldens, R. Willemze, T. de Witte (University
Medical Centre Nijmegen, Nijmegen, The Netherlands) |
|
EFFICACY AND
RESPONSE TO INTRAVENOUS ANTI-D IMMUNOGLOBULIN IN REFRACTORY
CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA
K.M.A. Ramadan, M. El-Agnaf (Belfast City Hospital, Belfast,
United Kingdom) |
STUDY ON THE MECHANISM OF
HUMAN PLATELET AGGREGATION INDUCED BY SJAMP
T. Guo, S. Shanjun, H. Yu, W. Wenning, S. Di (Union Hospital,
Wuhan, Hubei, China) |
MOLECULAR ANALYSIS OF HAEMOPHILIA
B IN IRANIAN PATIENTS: THREE NEW MUTATIONS IN THE FIX GENE
G. Rastegar Lari, S. Enayat, P. Fard Esfahani, M. Rassoulzadegan,
F. Moghadam, J.M. Lavergne, F. Ala (Iranian Hemophilia Care
Center, Tehran, Iran) |
DEMOGRAPHIC DATA, OUTCOME
AND PROGNOSIS OF CHILDREN WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA
(ITP) IN ARGENTINA. RESULTS FROM A MULTICENTERED STUDY
H.C. Donato, A. Picón, M.C. Rapetti, A. Rosso, G. Schvartzman,
C. Drozdowski, J.J. Di Santo (Policlinico Bancario, Buenos Aires,
Argentina) |
MANAGEMENT OF IDIOPATHIC
THROMBOCYTOPENIC PURPURA OF THE LEBANESE CHILDREN
C. Djambas Khayat, P. Noun (Hotel Dieu de France Hospital, Beirut,
Lebanon) |
CARTILAGE DAMAGE AND SYNOVIUM
CHANGES IN HAEMOPHILIC ARTHROPATHY: EVALUATION WITH MAGNETIC
RESONANCE IMAGING
P.E.M. Makris, I.N. Fotiadis, I.F. Girtovitis, A. Haritanti,
A.K. Boutou, A.S. Dimitriadis, P.E. Makris (Aristotle Univ.
Thessaloniki of Greece, Thessaloniki, Greece) |
THERAPY OF PATIENTS WITH
CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP): EFFICACY, TOLERABILITY,
AND SAFETY OF A NEW LIQUID INTRAVENOUS IMMUNOGLOBULIN
D. Milligan, A. Eden, I. Sklenar, C. Adams, I. Andresen, K.
Bender (Birmingham Heartlands Hospital, Birmingham, United Kingdom) |
HAEMATOLOGICAL FINDINGS AND
TREATMENT OF HAEMORRHAGIC DENGUE IN VENEZUELA
A.E. Soyano, A. Müller, A. Soyano, C. Cruz, R. Portillo,
H. Yépez, L. Vincenti, A. Utreras, J. Vargas, C. Cursio,
M. Durán, F. Ruiz (Clínica El -Vila, Caracas,
Venezuela) |
THE EFFECT OF
A NEW VASOPRESSIN ANALOG TERLIPRESSIN AND AMINO ACID GLYCINE
ON FVIII AND T -PA RELEASE
M.E. Grigorjeva, M.G. dr Golubeva (Lomonosov’s Moscow
State University, Moscow, Russian Federation) |
|
|
METABOLIC SYNDROME
AND ENDOTHELIAL DYSFUNCTION
P. Galajda, L. Sutarik, J. Stasko, L. Dulikova, B. Holman, M.
Jacmenikova, M. Ochodnicky, P. Kubisz, M. Mokan (Jessenius Faculty
of Medicine, Martin, Slovak Republic) |
THROMBOMODULIN
AND INTERCELLULAR ADHESION MOLECULE- 1 LEVELS IN PATIENTS WITH
THALASSEMIA INTERMEDIA AND SICKLE CELL SYNDROMES
I. Papassotiriou, I. Kanavaki, M. Vounatsou, C. Lazaropoulou,
M. Tsironi, I. Rombos (“Aghia Sophia” Children’s
Hospital, Athens, Greece) |
TAFI AND METABOLIC
BALANCE IN DIABETIC NEPHROPATHY
J. Stasko, J. Ivankova, B. Holman, P. Galajda, L. Plank, P.
Kubisz (Jessenius Medical School, Martin, Slovak Republic) |
ENDOTHELIAL FACTORS
AND ADHESION MOLECULES IN CHILDREN AND ADOLESCENTS WITH SICKLE
CELL DISEASE
E.S. Hatzipantelis, M. Athanassiou-Metaxa, A. Taparkou, V. Tzimouli,
N. Gombakis, D. Kleta, I. Tsatra, A. Koussi, H. Tsantali, F.
Kanakoudi- Tsakalidou (Hippokration General Hospital, Thessaloniki,
Greece) |
VARIABLE PROTECTION
FROM THROMBOTIC STIMULI IN P-SELECTIN GLYCOPROTEIN LIGAND-1
DEFICIENCY
J. Kappelmayer, K. Miszti-Blasius, L. Xia, R.P. McEver (Medical
School, University of Debrecen, Debrecen, Hungary) |
KINETIC OF MOBILIZATION
OF ENDOTHELIAL PRECURSORS AFTER ACUTE MYOCARDIAL INFARCTION
R. Giordano, C. Borsotti, L. Lazzari, A. Colombo, E. Piccaluga,
P. Rebulla, G. Lambertenghi Deliliers, D. Soligo (Cell Factory
Ospedale Maggiore Policlini, Milan, Italy) |
VASCULAR/LYMPHATIC
ENDOTHELIAL PROGENITOR CELLS ARE MORE ENRICHED IN HUMAN CORD
BLOOD IN EARLY GESTATIONAL WEEKS
Y. Gunji, T. Ohki, N. Takahashi, Y. Honma, K. Alitalo, M.Y.
Momoi (Jichi Medical School, Tochigi-Ken, Japan) |
THROMBOPOIETIN
(TPO) LEVELS IN HEPATIC PATIENTS WITH THROMBOCYTOPENIA
S. Aref, M. Mabed, T. Selim, N. Khaphagy (Mansoura Faculty of
Medicine, Mansoura, Egypt) |
DECREASED PLATELET ACTIVATION
AND ENDOTHELIAL DYSFUNCTION AFTER PERCUTANEUS MITRAL BALLON
VALVULOPLASTY
M.S. Ayaz (T Yuksek Ihtisas Hospital, Ankara, Turkey) |
ADRENALINE AND LYSOPHOSPHATIDIC
ACID ACTS SYNERGISTICALLY TO INCREASE PLATELET ADHESION TO ALBUMIN
A.C. Eriksson, U.K. Nilsson, P.A. Whiss (Fact.of Health Sc.,
Div. of Pharmacology, Linköping, Sweden) |
|
PLATELET LARGER
CELL RATIO (P-LCR) IN PATIENTS WITH DYSLIPIDEMIA
H.Z.W. Grotto, J.F.A. Noronha (State University of Campinas,
Campinas, Brazil) |
MULTIPLE PLATELET FUNCTION
DEFECTS IDENTIFIED BY FLOW CYTOMETRY IN A CONSECUTIVE COHORT
OF 50 PATIENTS AT DIAGNOSIS OF AML
E.B. Leinoe, E. Kjaersgaard, E. Gaarsdal, H.E. Johnsen (Herlev
University Hospital, Herlev, Denmark) |
NO EPISODE OF THROMBOCYTOPENIA
AFTER FOUR-WEEK ADMINISTRATION OF FONDAPARINUX, A NEW SYNTHETIC
AND SELECTIVE INHIBITOR OF FACTOR XA, IN THE PENTHIFRA-PLUS
STUDY
M.R. Lassen, B.I. Eriksson (Spine Clinic Hoersholm Hospital,
Hoersholm, Denmark) |
RAPID DETECTION OF INHIBITORS
OF THE VON WILLEBRAND FACTOR-CLEAVING PROTEASE (ADAMTS-13) USING
A NOVEL SEMI-AUTOMATED ASSAY
V.V. Kostousov, T. Bombeli, J. Fehr (University Hospital of
Zürich, Zürich, Switzerland) |
PLATELET ACTIVATION DURING
STRESS IN HYPERHOMOCYSTEINAEMIC RATS
N. Pavlova, S.V. Alisievitch, K.A. Tcherkasova, E.P. Romanova,
I.A. Rudko, A.A. Kubatiev (Institute of General Pathology, Moscow,
Russian Federation) |
SEVERE CONSTITUTIONAL ADAMTS-13
DEFICIENCY IN CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA
PRESENTING WITH APPARENT ADAMTS-13 INHIBITOR DUE TO HEMOGLOBIN
IN HEMOLYTIC PLASMA
J.D. Studt, J.A. Kremer Hovinga, G. Antoine, M. Hermann, M.
Rieger, F. Scheiflinger, B. Lämmle (Inselspital, University
Hospital, Bern, Switzerland) |
THROMBOTIC THROMBOCYTOPENIC
PURPURA: 24 YEARS OF EXPERIENCE AT THE AMERICAN UNIVERSITY OF
BEIRUT MEDICAL CENTER
T. Taher, A. Shamseddine, T. Saliba, E. Aoun, A. Chahal, N.
El-Saghir, Z. Salem, A. Bazarbachi, M. Khalil (American University
of Beirut, Beirut, Lebanon) |
TREATMENT OF MULTIPLE RELAPSING
THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) WITH AZATHIOPRINE
R. Putzulu, L. Laurenti, M. Bianchi, N. Piccirillo, F. Sorà,
P. Chiusolo, M. Tarnani, P. Piccioni, S. Rutella, F. Peyvandi,
S. Sica, G. D’Onofrio, G. Leone (Policlinico A. Gemelli,
Roma, Italy) |
|
|
RESULTS OF A
DIGITAL WEB BASED EXERCISE FOR UK NEQAS(H), BLOOD CELL AND BONE
MARROW MORPHOLOGY SCHEME.
E.J. Wells, J. Ardern, L. Hickman, M. Brereton, J. Burthem,
R. Bromilow, L. Seal, B. De la Salle, P. McTaggart, J. Parker-Williams,
K. Hyde (Manchester, Manchester, United Kingdom) |
DIFFERENCES IN
TREATMENT PRACTICE, RESPONSE RATES AND COST OF EPOETIN ALFA
AND DARBEPOETIN ALFA TREATMENT FOR ANEMIC CANCER PATIENTS: A
RETROSPECTIVE ANALYSIS FROM SWEDEN
U. Persson, S. Borg, S. Jansson, T. Ekman, L. Franksson, S.
Friesland, A.M. Larsson (IHE, Swedish Inst. for Health Economics,
Lund, Sweden) |
INCREASING INCIDENCE
OF LYMPHOPROLIFERATIVE DISORDERS IS NOT ASSOCIATED WITH SICK
LEAVE DUE TO DEPRESSIVE DISORDERS
K. Nordström, F. Granath, M. Björkholm, A . Ekbom
(Karolinska University Hospital Solna, Solna, Sweden) |
CLINICAL RESEARCH
IN THE GERMAN COMPETENCE NETWORK “ACUTE AND CHRONIC LEUKEMIAS”
U. Berger, C. Aul, Th. Büchner, H. Döhner, G. Ehninger,
A. Ganser, N. Gökbuget, J. Hasford, D. Hoelzer, K. Überla,
R. Hehlmann (III. Medizinische Universitätsklinik, Mannheim,
Germany) |
CLINICAL SIGNIFICANCE
OF DIFFERENCES AND CHANGES IN QUALITY OF LIFE SCORES: EVALUATION
OF 424 MULTIPLE MYELOMA PATIENTS COMPLETING THE EORTC QLQ-C30
QUESTIONNAIRE
G. Wisloff, N. Gulbrandsen, M.J. Hjermstad (Ulleval University
Hospital, Oslo, Norway) |
WEB-BASED EUROPEAN
EDUCATION TRAINING AND ACCREDITATION PROGRAM IN HEMATOLOGY:
LEONARDO DA VINCI EC PILOT PROJECT (AGREEMENT NUMBER: 2002 –
4518 / 001 – 001)
G. Zini, E. Montserrat, R. Foà (Catholic University of
Sacred Heart, Rome, Italy) |
THE COST-EFFECTIVENESS
OF EPOETIN ALFA (EPREX) AND DARBEPOETIN ALFA (ARANESP) IN THE
TREATMENT OF CHEMOTHERAPY- RELATED ANEMIA
B.A. van Hout, D.D. Gagnon (Academic Medical Center, Utrecht,
The Netherlands) |
EVIDENCE-BASED,
NOVEL COMPARISON BETWEEN EPOETIN ALFA, EPOETIN BETA, AND DARBEPOETIN
ALFA BASED ON DRUG USE, EFFICACY AND TREATMENT COSTS IN DAILY
ONCOLOGICAL CLINICAL PRACTICE
B. Reichardt (Burgenländische Gebi, Eisenstadt, Austria) |
|
EVALUATION OF
THE COGNITIVE EFFECTS OF ONCE-WEEKLY EPOETIN ALFA IN ANEMIC
PATIENTS WITH HEMATOLOGIC CANCERS RECEIVING CHEMOTHERAPY: PRELIMINARY
RESULTS OF THE EPOLYM TRIAL
H. Tesch, C. Gisselbrecht, N. Ifrah (Bethanien-Krankenhaus,
Frankfurt, Germany) |
EPOETIN ALFA IMPROVES HEMOGLOBIN
LEVELS AND QUALITY OF LIFE PARAMETERS IN ANEMIC PATIENTS WITH
HEMATOLOGIC MALIGNANCIES RECEIVING CHEMOTHERAPY: INTERIM RESULTS
FROM THE EPOLYM TRIAL
F. Dammacco, N. Marschner, M. Gambacorta (University of Bari,
Bari, Italy) |
EPOETIN ALFA IMPROVES QUALITY
OF LIFE IN CANCER PATIENTS: RESULTS OF A META-ANALYSIS
M. Jones, B. Schenkel, J. Just, L. Fallowfield (J & J Pharmaceutical
Services, LLC, Raritan, NJ, USA) |
ASSOCIATION OF
MDR1 POLYMORPHISMS WITH DRUG RESISTANCE RISK IN PATIENTS WITH
LYMPHOPROLIFERATIVE DISORDERS
O.B. Goreva, A.Y. Grishanova, O.V. Mukhin, N.P. Domnikova, V.V.
Lyakhovich (Molecular Biology and Biophysics SB RAMS, Novosibirsk,
Russian Federation) |
EFFECTS OF IMATINIB
MESYLATE ON NORMAL HAEMOPOIETIC PROGENITORS
J. Perez-Oteyza, M. Perez-Abad, P. Ramos, P. Herrera, M.L. Ramos,
C. Montero, P. Gonzalez-Porque, J.L. Navarro (Hospital Ramon
y Cajal, Madrid, Spain) |
EFFECT OF DIOXIN
ON HUMAN NORMAL HEMATOPOIETIC AND LEUKEMIC CELLS
G. Lambertenghi Deliliers, F. Servida, N. Fracchiolla, P.A.
Bertazzi, D. Soligo (IRCCS Ospedale Maggiore, Milan, Italy) |
DEVELOPMENT OF
A NOVEL BIOSENSOR TO TO MONITOR ARA-C UPTAKE AND ASPECTS OF
INTRACELLULAR METABOLISM BY AML CELLS
M.A. Smith, V.C. Salisbury, J.E. Angell, H.M. Alloush (University
f the West of England, Bristol, United Kingdom) |
THE USE OF ANAGRELIDE
FOR CONTROL OF THROMBOCYTHAEMIA
G. Benson, R. Desmond, E. Conneally, M.F. McMullin (Belfast
City Hospital, Belfast, Northern Ireland) |
SAFETY EXPERIENCE
WITH TRISENOX® (ARSENIC TRIOXIDE) INJECTION
C. Oliva, B. Kirkhart, M.S. Maxon, R. Earhart (Cell Therapeutics,
Inc., Bresso, Milan, Italy) |
|
|
INFLUENCE OF
FUNCTIONAL POLYMORPHISM IN MDR1 GENE ON GENETIC PREDISPOSITION
AND PROGNOSIS IN ADULT ACUTE LEUKEMIA
K. Jamroziak, E. Balcerczak, P. Smolewski, B. Cebula, M. Kowalczyk,
M. Panczyk, M. Mirowski, W. Mlynarski, T. Robak (Medical University
of Lodz, Lodz, Poland) |
EXPRESSION OF
THE MULTIDRUG RESISTANCE PROTEINS MDR1, MRP1 AND LRP IN RELATION
TO DE NOVO ACUTE MYELOID LEUKEMIA TREATMENT OUTCOME
M. Podolak-Dawidziak, D. Dus, M. Kielbinski, M. Paprocka, M.
Kuliszkiewicz-Janus, I. Prajs, K. Kuliczkowski (Medical University,
Wroclaw, Poland) |
THIOPURINE S-METHYLTRANSFERASE
GENETIC VARIATION IN SERBIAN CHILDREN WITH ACUTE LYMPHOBLASTIC
LEUKEMIA
B. Petrucev, J. Urosevic, J. Poznanic, N. Tosic, L. Krivokapic
Dokmanovic, D. Janic, S. Pavlovic (Inst Mol Gen and Gen Eng
(IMGGE), Belgrade, Serbia) |
BIFOSFINIC PALLADACYCLE
COMPLEX DERIVED FROM N,N-DIMETHYL-1-PHENETHYLAMINE AND THE LIGAND
1,1’BIS(DIPHENYLPHOSPHINE)FERROCENE INDUCES APOPTOSIS
IN HL60 AND JURKAT CELL LINES IN THE PRESENCE OF NORMAL BCL-2
EXPRESSION.
C. Bincoletto, M.C.M. Smith, C.O. Rocha, G.Z. Justo, C.K. Matsumoto,
A.C.F. Caires, R.C. Araújo (CIIB, Mogi Das Cruzes, Brazil) |
SNP MINING BY
NANOGEN DEVICE: A SENSITIVE TOOL FOR THE IDENTIFICATION OF BCR/ABL
MUTATIONS IN CHILDHOOD PH+ALL
B. Corradi, R. Piazza, K. Monn, G. Masera, C. Gambacorti Passerini,
A. Biondi, G. Cazzaniga (Centro Ricerca Tettamanti, Monza, Italy) |
CD80 AND CD38
EXPRESSION AND EX-VIVO CHEMOSENSITIVITY TO PURINE ANALOGUES
IN CHRONIC LYMPHOCYTIC LEUKAEMIA
I. Del Giudice, A.G. Bosanquet, J. Durant, K. Owusu-Ankomah,
A. Morilla, R. Morilla, E. Matutes, D. Catovsky (Royal Marsden
Hospital-ICR, London, United Kingdom) |
THE EXPRESSION
OF MULTIDRUG RESISTANCE PROTEINS IN RELATION TO ZAP-70 EXPRESSION
IN B-CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
S. Narat, N.I. Folarin, R.J. Baker, D.T. Jones, S.M. Hart, R.G.
Wickremasinghe, A.V. Hoffbrand, A.B. Mehta, K. Ganeshaguru (Royal
Free & UC Medical School, London, United Kingdom) |
ANALYTICAL METHODOLOGY
AND PHARMACOKINETICS OF CAMPATH-1H IN PATIENTS WITH CLL AFTER
IV OR SC ADMINISTRATION
M. Montagna, M.A. Avanzini, M. Lazzarino, F. Locatelli, M. Montillo,
C. Rusconi, E. Morra, M.B. Regazzi (IRCCS-Policlinico S.Matteo,
Pavia, Italy) |
|
TIME TO RESPONSE
OF ASPERGILLUS ANTIGEN TO CASPOFUNGIN COMPARED TO AMPHOTERICINE
B : A SMALL RETROSPECTIVE STUDY
H. De Samblanx, M. Van De Vyvere, A. Van Mechelen, P. Zachée
(Stuivenberg Antwerp Belgium, Antwerp, Belgium) |
UBF EXPRESSION
AND RIBOSOMAL SYNTHESIS IN PHA STIMULATED LYMPHOCYTES TREATED
WITH N-BUTYRIC ACID
I. Kalousek, P. Otevrelova (Institute of Hematology, Prague,
Czech Republic) |
A ROLE OF MUTATION
OF CXCR4 GENE IN TWIN SISTERS WITH WHIM SYNDROME
S. Taniuchi, Y. Fujii, M. Masuda, T. Ito, S. Tsuji, M. Hasui,
Y. Hatano, Y. Kobayashi (Kansai Medical University, Moriguchi,
Japan) |
AN INVESTIGATION
OF THE PRO-APOPTOTIC EFFECT OF THE MEK INHIBITOR U0126 ALONE
AND COMBINED WITH ARA-C IN ACUTE MYELOID LEUKAEMIA, NON-LEUKAEMIC
NEOPLASTIC DISORDERS AND NORMAL HAEMOPOIETIC PROGENITORS
M.A. Smith, V.C. Salisbury, J.E. Angell, H.M. Alloush, P. Alton,
J.G. Smith (University of the West of England, Bristol, United
Kingdom) |
BCL-2 INHIBITORS
SENSITIZE TRAIL-INDUCED APOPTOSIS BY UNCOUPLING OF MITOCHONDRIAL
RESPIRATION IN HUMAN LEUKEMIC CELLS
L.J. Jia, J.H. Hao, M. Yu, F.T. Liu, A.C. Newland, L. Jia (ICMS,
Barts and the London, London, United Kingdom) |
ROLE OF STROMAL
CELLS IN REGULATION OF THE HUMAN PRIMITIVE HEMATOPOIETIC STEM
CELLS
L.P. Gerasimova, K. Momotjuk, G. Miterev (Hematological Scientific
Center, Moscow, Russian Federation) |
THE PROMYELOCYTIC
LEUKEMIA ZINC FINGER (PLZF) PROTEIN DOWN-REGULATES APOPTOSIS
AND EXPRESSION OF THE PRO-APOPTOTIC BID PROTEIN IN LYMPHOCYTES
A. Parrado, M. Robledo, M.R. Moya-Quiles, M.V. Bernardo, M.
Montes-Casado, M.J. Majado, C. Chomienne, R.A. Padua, M.R. Lvarez-López
(Hospital Virgen de la Arrixaca, Murcia, Spain) |
EVIDENCE FOR
RAD51-MEDIATED DNA REPAIR UP-REGULATION IN AML PATIENTS WITH
FLT3 INTERNAL TANDEM DUPLICATIONS
C.H. Seedhouse, H.H. Hunter, I. Carter, M. Pallis, M. Grundy,
N. Russell (University of Nottingham, Nottingham, United Kingdom) |
ACTIVATED GAMMA/DELTA
T CELLS EXPRESS THE NATURAL CYTOTOXICITY RECEPTOR NKP44
M. von Lilienfeld-Toal, J. Nattermann, G. Feldmann, I.G.H. Schmidt-Wolf
(Uniklinik Bonn, Bonn, Germany) |
|
|
THE EXPRESSION
OF CHEMOKINE RECEPTOR CXCR3 IN LYMPH NODES OF LYMPHOMAS AND
LYMPHOID REACTIVE TISSUE
G. Mazur, T. Wrobel, A. Halon, K. Kuliczkowski (Wroclaw Medical
University, Wroclaw, Poland) |
HUMAN MASK, A
MULTIPLE ANKYRIN REPEAT SINGLE KH DOMAIN PROTEIN INTERACTS WITH
SHP2 IN K562 CELL LINE
F. Traina, A.S.S. Duarte, P.M.B. Favaro, S.S. Medina, I.C. Carvalho,
M.J.A. Saad, S.T.O. Saad (State University of Campinas, Campinas,
Brazil) |
TRANSFORMING
GROWTH FACTOR-BETA1 (TGF-BETA1) ENHANCES ADHESION OF HAIRY CELLS
TO BONE MARROW
FIBROBLASTS VIA VLA-4 / VCAM-1 M. Shehata, M. Hilgarth, R. Hubmann,
M. Duechler, J.D. Schwarzmeier (Vienna University, Vienna, Austria) |
EARLY HEMATOPOIETIC
ZINC FINGER (EHZF), A MULTIFUNCTIONAL TRANSCRIPTION CO-FACTOR
EXPRESSED IN HUMAN EARLY HAEMATOPOIETIC CELLS AND MYELOID LEUKAEMIC
BLASTS
G. Morrone, H.M. Bond, M. Mesuraca, N. Amodio, S. Lupisella,
L. Serravalle, M. Di Nicola, A.M. Gianni, M.A.S. Moore, M. Grieco,
S. Venuta (University of Catanzaro Magna Græcia, Catanzaro,
Italy) |
ERYTHROPOIETIC
ACTIVITY INTERFERES WITH RED CELL PARAMETERS IN HEMODIALYSIS
PATIENTS
C. Bovy, Y. Beguin, A. Gothot, G. Rorive, J.M. Krzesinski (CHU
Sart-Tilman, Liège, Belgium) |
EFFECT OF ERYTHROPOIETIC
ACTIVITY AND CELL VOLUME ON RBC PARAMETER DETERMINATION: COMPARISON
WITH MATURE ERYTHROCYTE INDICES
C. Bovy, A. Gothot, J.M. Krzesinski, G. Rorive, Y. Beguin (CHU
Sart-Tilman, Liège, Belgium) |
ERYTHROPHAGOCYTOSIS
BY HUMAN MACROPHAGES INTERFERES WITH THEIR ANTI-BACTERIAL EFFECTOR
FUNCTIONS
E. Wiener, I.A.G. Roberts (Imperial College, Hammersmith Hospital,
London, United Kingdom) |
INVESTIGATION
OF ACTIVATED T-CELLS IN NON-HODGKIN LYMPHOMA PATIENTS
L.V. Varoczy, L. Gergely, M. Aleksza, G. Vadasz, Z. Simon, A.
Illes (University of Debrecen, Debrecen, Hungary) |
THE IMPACT OF
BASELINE HEMOGLOBIN ON TRANSFUSION REDUCTION, HEMOGLOBIN RESPONSES
AND QUALITY OF LIFE IN BREAST CANCER PATIENTS ON CHEMOTHERAPY
RECEIVING ONCE WEEKLY 40,000 IU EPOETIN ALFA
F. Couture, J. Chang, S. Young, C.Y. Lau, K.L. McWatters (Hôtel-Dieu
de Quebec, Quebec, Canada) |
|
TREATMENT OF
ANEMIA USING RECOMBINANT HUMAN ERYTHROPOIETIN (R-HUEPO) IN PATIENTS
TREATED WITH CHEMOTHERAPY : PROSPECTIVE SURVEY TO CREATE A BELGIAN
DATA BASE (BEPOS)
A. Bosly, M. Boogaerts, D. Bron, Y. Humblet, L. Noens, R. Paridaens,
D. Piccart, S. Van Belle (UCL Mont-Godinne, Yvoir, Belgium) |
EARLY INCREASE
IN IMMATURE RETICULOCYTE FRACTION PREDICTS RESPONSE TO RHUEPO
THERAPY IN VERY LOW BIRTH WEIGHT PREMATURE INFANTS
F. Corazza, L. Pécheux, D. Blum, F. Corazza (CHU-Brugmann,
Brussels, Belgium) |
EPOETIN BETA
(NEORECORMON) ONCE WEEKLY OR THREE-TIMES WEEKLY PRODUCES A RAPID
HAEMOGLOBIN RESPONSE IN ANAEMIC PATIENTS WITH LYMPHOPROLIFERATIVE
MALIGNANCIES
B. Coiffier, N. Milpied, T. Facon, P. Beris (Centre Hôspitalier
Lyon-Sud, Pierre-Benite, France) |
RED BLOOD CELL
AGING PATTERNS: IN VITRO OBSERVATIONS USING ATOMIC FORCE MICROSCOPY
S.M.M. Magalhães, M.S. Pitombeira, F.D. Rocha Filho,
M.D.M. Braga, L.L. Pinheiro, L.M.A. Ramos, J.A.K. Freire, V.N.
Freire, G.A. Farias, E.F. da Costa, E.F. da Silva Jr., L.M.
Rebelo (Universidade Federal do Ceará/ Hemoce, Fortaleza,
Brazil) |
EFFECT OF ANAEMIA
CORRECTION WITH EPOETIN BETA (NEORECORMON) ONCE WEEKLY ON PERFORMANCE
STATUS AND DISEASE RESPONSE
I. Spicka, Y. Beguin (Charles University, Prague, Czech Republic) |
PERIPHERAL BLOOD
MONONUCLEAR CELLS FROM PATIENTS WITH CHRONIC RENAL FAILURE SUPPRESS
ERYTHROPOIESIS IN VITRO VIA THE PRODUCTION OF TUMOR NECROSIS
FACTOR ALPHA
N. Karakolios, C. Tsatalas, D. Pantelidou, P. Passadakis, P.
Chalkia, E. Spanoudakis, D. Margaritis, E. Thodis, A. Kortsaris,
V. Vargemezis, G. Bourikas (University Hospital of Alexandroupolis,
Alexandroupolis, Greece) |
MECHANISMS INVOLVED
IN FETAL HEMOGLOBIN ELEVATION IN ADULT ERYTHROID CELL CULTURES
TREATED WITH HYDROXYUREA
A. Likousi, G. Paterakis, D. Koumbi, A. Tserga, M. Papadakis,
I. Karakatsanis, G. Androutsos, K.E. Sekeri, D. Kletsas, C.
Belessi, M. Georgiakaki, M. Katelani, E. Fibach, N. Vamvakopoulos,
B. Merianou, P. Kollia (School of Medicine, Univ. of Thessaly,
Larissa, Greece) |
IMPACT OF RHUEPO
(EPOETIN BETA) ON SURVIVAL OF PATIENTS WITH LYMPHOPROLIFERATIVE
MALIGNANCIES: LONG-TERM FOLLOW-UP OF A LARGE RANDOMISED STUDY
A. Österborg, Y. Brandberg, M. Hedenus (Karolinska University
Hospital, Stockholm, Sweden) |
|
|
PREDICTION OF
RESPONSE OF ANEMIA TO RECOMBINANT HUMAN ERYTHROPOIETIN IN PATIENTS
WITH MULTIPLE MYELOMA AND LYMPHOMA: EVALUATION AND INTERIM ANALYSIS
OF TRADITIONAL AND NOVEL PREDICTIVE MARKERS
E. Katodritou, M. Speletas, D. Kapetanos, K. Zervas, I. Korantzis,
M. Sion, J. Christakis (Papageorgiou General Hospital, Thessaloniki,
Greece) |
EFFECTS OF POPULATION
DEFINITIONS AND STUDY ENDPOINTS ON EFFICACY OF EPOETIN ALFA
VS PLACEBO IN ANEMIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES
RECEIVING CHEMOTHERAPY
T. Littlewood, M. Zagari, B. Schenkel (John Radcliffe Hospital,
Oxford, United Kingdom) |
TRANSFERRIN MODULATES
TNF PRODUCTION ON HUMAN IMMUNE CELLS: ROL OF TRANSFERRIN RECEPTOR
G. Munoz, E. Rios, M. Lopez, L. Schlesinger, M. Olivares (Institute
of Nutrition (INTA), Santiago, Chile) |
PREVALENCE OF
C282Y, H63D AND S65C MUTATIONS OF HFE GENE IN 1146 NEWBORNS
FROM A REGION OF NORTH SPAIN
A.A.H. Altes, A. Ruiz, M.J. Barcelo, A.F. Remacha, M.T. Puig,
A.J. Maya, C. Castell, J.M. Amate, Z. Saz, M. Baiget (Hospital
Esperit Sant, Sta Coloma De Gramenet, Spain) |
PHARMACODYNAMICS
OF REPEAT DOSE ORAL ADMINISTRATION OF GT56-252 IN IRON- LOADED
CEBUS MONKEYS
M.P. Bree, J.K. Marquis, J.L. Wagner, J. Bell (Genzyme, Waltham,
USA) |
THE STUDY OF
THE COMPLEX FORMATION BETWEEN SOLUBLE TRANSFERRIN RECEPTOR AND
TRANSFERRIN
V. Filatov, A.E. Kogan, O.V. Kolosova (Moscow State University,
Moscow, Russian Federation) |
FUNCTIONAL CHARACTERISTICS
OF DENDRITIC CELLS (DC) AND ACTIVATED LYMPHOCYTES IN APLASTIC
ANEMIA (AA) PATIENTS
S. Archuadze, E. Sadovnikova, E.A. Michailova, E.N. Parovichnikova,
V.G. Savchenko (National Research Centre for Haematology, Moscow,
Russian Federation) |
TNF-ALPHA CAUSES
AN AUTOCRINE IFN-GAMMA RESPONSE IN CD34+ CELLS
M. Attia, J.P. Welsh, K.L. Laing, F.M. Gibson, T.R. Rutherford
(St. George’s Hospital Medical School, London, United
Kingdom) |
THE SAFETY AND
PHARMACOKINETICS OF GT56-252, A NOVEL ORALLY AVAILABLE IRON
CHELATOR
J.M. Donovan, P.A. Palmer, M.A. Plone, B. Wonke (Genzyme Corporation,
Waltham, MA, USA) |
|
COMBINED CHELATION
THERAPY IN THALASSAEMIA MAJOR: HOW LONG IT TAKES TO REDUCE BODY
IRON OVERLOAD AT SAFETY MARGINS?
K. Farmaki, A. Patsoura, M. Posantzis, E. Gotsis (General Hospital
of Corinth, Corinth, Greece) |
DO ANDROGENS
AND CYTOGENETIC COULD EXPLAIN LOW INCIDENCE OF SECONDARY LEUKEMIAS
IN ACQUIRED APLASTIC ANAEMIA TREATED WITH IMMUNOSUPPRESSIVE
THERAPY
L. Terriou, J. Andrieux, A. Duhamel, C. Berthon, J.B. Micol,
F. Kuhnovski, R. Guieze, S. Corm, M.P. Noel, F. Bauters, T.
Facon, J.L. Lai, P. Fenaux, X. Leleu (CHU, Lille, France) |
EXTRAHEPATIC
HEPCIDIN SYNTHESIS IN LIPOPOLYSACCHARIDETREATED MICE
J. Krijt, M. Vokurka, E. Necas (Charles University, 1st Medical
Faculty, Prague, Czech Republic) |
FREQUENCY AND
PHENOTYPE OF MUTATION S65C IN 550 PATIENTS WITH SUSPECTED IRON
OVERLOAD
S. Franke, J.L. Rummens, M. Raymaekers, V. Peeters, G. Bries,
R. Cartuyvels (Virga Jesse Hospital, Hasselt, Belgium) |
DETERMINANTS
OF SERUM FERRITIN IN THE METABOLIC SYNDROME
C. Bozzini, O. Olivieri, G. Villa, N. Martinelli, A. Bassi,
F. Pizzolo, S. Friso, V. Lotto, R. Corrocher, D. Girelli (Policlinico
GB Rossi, Verona, Italy) |
BLOOD DENDRITIC
CELLS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA
M. Mohty, N. Ben Mami, H. Chambost, D. Blaise, B. Gaugler, D.
Olive (Institut-Paoli-Calmettes, Marseille, France) |
PERIPHERAL BLOOD
IMMUNOPHENOTYPING BY FLOW CYTOMETRY IN LOW GRADE MYELODYSPLASTIC
SYNDROMES
E. Rios Herranz, A. Marin Niebla, G. Rodríguez Garcia,
A. Martin Noya, D.A.R. Alonso, R.P.R. Parody, J.M. Rodriguez
Fernandez (Hospital Virgen del Rocio, Seville, Spain) |
HUMAN CD40 LIGAND
GENE TRANSFER INTO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) B-CELLS
VIA EBV-BASED VECTORS
E. Hettich, A. Janz, B. Weissflog, B. Neuhierl, E. Hellebrand,
W. Hammerschmidt, R. Zeidler (GSF, Munich, Germany) |
MONITORING FLT3
ANTIGEN EXPRESSION IN ACUTE LEUKAEMIA USING FLOW CYTOMETRY
C.D. Ridler, F. Ebrahim, M. Smith, T. Milne, M. Macey, A.Z.S.
Rohatiner, T.A. Lister, J. Amess, J.D. Cavenagh, S.G. Agrawal
(Bart’s and the London NHS Trust, London, United Kingdom) |
|
|
FLOW CYTOMETRIC
ANALYSIS OF THE TCRVBETA REPERTOIRE IN PATIENTS WITH SUSPECT
T-CELL PROLIFERATIONS
I. Kakkas, A. Psarra, V. Kapsimali, D. Kouniaki, M. Nikolopoulou,
M. Bakiri, E. Nikiforakis, C. Papasteriades (Evangelismos, Athens,
Greece) |
KIR ASSAY AND
ITS CLINICAL IMPLICATIONS IN ADULT PATIENTS WITH ACUTE MYELOID
LEUKEMIA USING FLOW CYTOMETRY
H.J. Kim, B.H. Park, Y. Choi, W.S. Min, C.C. Kim (CHSCTC,St.
Mary’s Hospital, Seoul, South-Korea) |
QUANTITATIVE
ANALYSIS OF EXPRESSION OF CD34, GROWTH FACTORS RECEPTORS, SDF-1-ALPHA-
AND ADHESION MOLECULE CD49D ON CD34+ PERIPHERAL BLOOD CELLS
AFTER MOBILIZATION WITH CYTOTOXIC DRUGS AND/OR G-CSF
B. Marianska, J. Kopec-Szlezak, J. Wozniak, A. Szczepinski,
B. Nasilowska (Institute of Hematology, Warsaw, Poland) |
TRANSFECTION
OF IVT MRNA OF TRAIL AND TUMOR ANTIGENS (SART-1 AND WT-1) INTO
DENDRITIC CELLS
M. Narita, A. Saitoh, A. Sekiguchi, A. Yokoyama, N. Watanabe,
N. Satoh, T. Yano, F. Ayres, L. Alldawi, T. Abe, N. Tsukada,
K. Toba, T. Furukawa, K. Takai, T. Koike, M. Takahashi (Faculty
of Medicine, Niigata, Japan) |
COMPARED ANALYSIS
OF DENDRITIC CELLS AND THEIR SUBSETS IN THE LATE POSTRANSPLANT
PERIOD BETWEEN PATIENTS UNDERGOING ALLO-SCT AND THEIR RESPECTIVE
SIBLING DONORS
F.M. Sanchez-Guijo, L.I. Sanchez-Abarca, M.D. Caballero, E.M.
Villaron, M. Alberca, N. Lopez-Holgado, J.A. Perez- Simon, C.
Bueno, M.C. del Cañizo, A. Orfao, J.F. San Miguel (Hospital
Universitario de Salamanca, Salamanca, Spain) |
SUCCESFUL RETROVIRAL
GENE TRANSFER IN STEM CELLS EXPANDED WITH FIBROBLAST GROWTH
FACTOR-1 (FGF-1) AS A SINGLE CYTOKINE
A. Crcareva, T. Saito, A. Kunisato, A. Stojanovic, O. Karanfilski,
L. Cevreska, K. Kumano, H. Hirai, S. Chiba (University of Tokyo
Hospital, Tokyo, Japan) |
RE-EXPRESSION
OF P15 (INK4B) GENE IN KG1A CELL LINE INDUCED BY IN VITRO INHIBITION
OF DNA METHYLTRANSFERASES AND HISTONE DEACETYLASES
A. Valencia, C. Garcia, J. Cervera, M.Z. Garcia-Casado, J.C.
Pajuelo, E. Barragan, P. Bolufer, M.L. Perez-Sirvent, A. Sempere,
M.J. Remigia, M.L. Marty, M.A. Sanz (Hospital Universitario
“La Fe”, Valencia, Spain) |
|
|
